People

Julian Castelli is venture partner at Next Coast Ventures, according to its current official roster. The firm’s published career biography records: Senior Technology + SaaS executive | Serial entrepreneur with proven track record of delivering growth across multiple industries. Outside executive and board references are reported as career history, with current status at each separate organisation not independently assumed.

Cotter Cunningham is venture partner at Next Coast Ventures, according to its current official roster. The firm’s published career biography records: Consumer Internet and Marketplace Executive | Founder, Chair and CEO RetailMeNot (NASDAQ:SALE) | COO Bankrate (NASDAQ:RATE). Outside executive and board references are reported as career history, with current status at each separate organisation not independently assumed.

Brian Sharples is venture partner at Next Coast Ventures, according to its current official roster. The firm’s published career biography records: Co-founder and CEO of HomeAway | Member Board Of Directors at Avalara | Stanford University Graduate School of Business | Former President and CEO of IntelliQuest Information Group. Outside executive and board references are reported as career history, with current status at each separate organisation not independently assumed.

Adam Rogers is venture partner at Next Coast Ventures, according to its current official roster. The firm’s published career biography records: Former intern, CTO & CEO at Ultimate Software | Partner at Next Coast Ventures investing in & advising early-stage companies. Outside executive and board references are reported as career history, with current status at each separate organisation not independently assumed.

Co-founded Atomontage in 2017. Game developer with experience creating Cortex Command and other interactive projects; the company’s August 2026 interview describes his role in rebuilding Virtual Matter with optional AI creation tools.

Atomontage co-founder and CEO, identified in the August 2026 interview linked and promoted by the company. Has developed the underlying voxel engine since 2004, drawing on a background in the demoscene.

Named by GGWP’s September 17, 2026 release as one of its four co-founders alongside George Ng, Dennis Fong and Kun Gao. This records an enduring founder relationship; the company’s current staff and board directory does not publish a current operating title for him.

GGWP co-founder and Chairman, confirmed by the September 17, 2026 company announcement. Focuses on long-term strategy, business development and major partnerships after transitioning from the CEO role.

Co-founder and CEO of GGWP; appointed CEO on September 17, 2026 after serving as President and founding CTO. Previously co-founded Cyence and served as Chief Data Scientist at Cray; holds a PhD in economics from UC Irvine.

Paul Rogers is venture partner at Next Coast Ventures, according to its current official roster. The firm’s published career biography records: CTO at Equipment Share | Former CTO at RetailMeNot and Namely | Opened Google's Austin office in 2008 | Led the BazaarVoice engineering team during its start-up years. Outside executive and board references are reported as career history, with current status at each separate organisation not independently assumed.

Julie Dodd is venture partner at Next Coast Ventures, according to its current official roster. The firm’s published career biography records: Operating Partner at Welsh, Carson, Anderson & Stowe | Award-Winning COO & CSO | Former COO, CSO and General Manager at Ultimate Software. Outside executive and board references are reported as career history, with current status at each separate organisation not independently assumed.

Laura Schenke is operations consultant at Next Coast Ventures, according to its current official roster. The firm’s published career biography records: Operations Consultant at Next Coast Ventures. Former Nationally Board Certified Health & Wellness Coach at Noom | Assistant GM at Big Onion Tavern Group | General Manager & Event Coordinator at VIP Chicago Parties | MS from Concordia University | BS from Eastern Illinois University. Outside executive and board references are reported as career history, with current status at each separate organisation not independently assumed.

Kaitlyn DeBernardo is partner, coo & head of platform at Next Coast Ventures, according to its current official roster. The firm’s published career biography records: Stanford GSB MBA Grad | Early employee at Workrise (formerly RigUp) which raised over $700mm from their Series B to E funding rounds while she was there | Bank of America Merrill Lynch on the equity desk in New York | Stanford Graduate School of Business | Columbia University with a BA in Economics. Outside executive and board references are reported as career history, with current status at each separate organisation not independently assumed.

Thomas Ball is co-founder and managing director at Next Coast Ventures, according to its current official roster. Also named Charles Thomas Ball in the adviser’s legal filing. The firm’s published career biography records: Co-Founder & Managing Partner at Next Coast Ventures | On the Board of Aclaimant, UpEquity, Enboarder: Experience-Driven Onboarding, CoPilot, TrustRadius, GOJA, GoodKind Co, KLRU-TV | Former General Partner at Austin Ventures | Former Investor of Outbound Engineer, and Bazaarvoice | Founder of Tahoe Domains, Inc. | Former CEO/Founder of Razorgator/Openfield Technology | Former VP of Business Development at Lifeminders | Former CEO/Founder of eCoupons | Former Principal at Discovery Capital | Former Engagement Manager at Mitchell Madison Group | MBA from Stanford University Graduate School of Business | BS in Finance from University of Florida.. Outside executive and board references are reported as career history, with current status at each separate organisation not independently assumed.

Mike Smerklo is co-founder and managing director at Next Coast Ventures, according to its current official roster. Also known as Michael Arthur Smerklo in the adviser’s legal filing. The firm’s published career biography records: Co Founder & Managing Director at Next Coast Ventures | Author of Mr. Monkey and Me, A real survival guide for entrepreneurs | Crowdhealth Board Member | Everly Health Board Member | Street Smarts VR Board Member | Submittable Board Member | BrainCheck Board Member | Former CEO of ServiceSource (SREV) | Former Director of Business Development of Opsware | MBA, Northwestern University - Kellogg School of Management | BS, Miami University of Ohio. Outside executive and board references are reported as career history, with current status at each separate organisation not independently assumed.

Michael Gutch, also published as Mike Gutch, was appointed Chief Financial Officer of Noema Pharma in2022 and was named in its2023 financing announcement. Michael Samar is the company’s current CFO, appointed in2025. Gutch’s exact departure day is not established.

John Kemp is the neuroscience scientist expressly identified by Noema Pharma’s December2020 issuer announcement as its Chief Scientific Officer. The company names his contribution to its early scientific foundations. Current tenure, an exact appointment date and an original portrait are not independently established.

Luigi Costa co-founded Noema Pharma and served as CEO through its early clinical development and Series A/B financing. The issuer’s June2023 announcement states that Ilise Lombardo succeeded him after he stepped down to pursue other opportunities. The exact departure day is not independently established.

Ali Mostajelean is a Noema Pharma scientific advisor and UCSF pediatric neurologist specializing in epilepsy. The company describes his clinical epilepsy and tuberous-sclerosis work at UCSF Benioff Children’s Hospital Oakland. UCSF’s own current provider directory corroborates his identity and supplies an authentic portrait.

Gerald Maguire is a Noema Pharma scientific advisor and a psychiatrist known for research on the medical treatment of stuttering. His published career includes psychiatry and neuroscience at UC Riverside and earlier academic work at UC Irvine. His UCR portrait is a genuine historical university image; it does not independently establish a current faculty appointment.

Andreas Hartmann is a Noema Pharma scientific advisor. The issuer’s2021 Tourette study announcement identifies him as a clinical expert at Sorbonne University and Pitié-Salpêtrière Hospital in Paris. This neurologist is distinct from similarly named management consultants, hydrology researchers and mathematical physicists. An authentic original portrait is not independently verified.

Tanjala Gipson is a Noema Pharma scientific advisor and pediatric neurologist. Her hospital’s current directory identifies her as director of its TSC-associated neuropsychiatric disorders clinic and a University of Tennessee Health Science Center professor in developmental pediatrics. Her clinical interests include tuberous sclerosis and neurodevelopmental disabilities.

Terence Coderre is a Noema Pharma scientific advisor and a McGill pain researcher. McGill’s primary directory identifies him as Harold Griffith Professor in Anesthesia Research. His work examines neuronal pain mechanisms and neuroplasticity in the spinal cord and brain.

Felice Verduyn-van Weegen is a Noema Pharma board member and an EQT Life Sciences partner. The company’s biography describes earlier work at LSP before its integration into EQT, and prior consulting at McKinsey. Noema’s December2024 extension announcement confirms her board appointment alongside EQT’s institutional investment.

Catherine Moukheibir is a Noema Pharma board member. Her career includes biotechnology board service, pharmaceutical management and finance, including previous leadership at MedDay Pharmaceuticals and Innate Pharma. The other board affiliations listed in her company biography are retained as published career context rather than independently asserted as current.

Arthur Franken is a Noema Pharma board member and is described by its published biography as a Gilde Healthcare general partner and founding-team member who joined in2001. His investment work includes biopharmaceuticals, medical technology, diagnostics and digital health. Gilde’s corporate investment is distinct from board membership or a personal check.

Darren Carroll is a Noema Pharma board member. Its biography describes his partnership at Polaris Partners from2020 and a prior22-year career at Eli Lilly, including leadership of global business development. Polaris’s institutional Noema investments are distinct from any personal holding.

Mehdi Ainouche is a Noema Pharma board member. Its published biography identifies him as a Jeito Capital partner with life-sciences investment experience across ophthalmology, oncology, CNS, cardiometabolic and neuromuscular conditions. His board membership does not by itself establish a personal investment in Noema. Mehdi joined Jeito Capital, a global leading independent Private Equity fund, with €534 million under management based in Paris and New York in 2020, following the launch of the fund, and was involved in several investments and portfolio companies notably in the fields of neurology, ophthalmology, oncology, cardiometabolic, neuromuscular diseases and fibrosis.  Prior to Jeito, Mehdi's last role was Associate within the healthcare venture team of Turenne Capital, a French investment group with over €1.8 billion under management, where he successfully participated to several investments in biotech & medtech. Mehdi holds a Pharmacy Doctorate from University of Rennes (France) and a Master in Business from ESCP Europe Business School Paris. Mehdi Ainouche is Jeito Capital’s current Partner. Joined 2020, became Partner 2025 following Principal and Senior Principal roles. Former Turenne healthcare investor; Rennes pharmacy doctorate and ESCP business masters.

Jeffrey Jonas is Chairman of Noema Pharma’s board. A neuroscience biotechnology executive, he served as Chief Executive Officer of Sage Therapeutics from2013 to2020 and previously held pharmaceutical leadership roles including at Shire. Older statements in Noema’s biography about subsequent Sage positions are historical context rather than independently reconfirmed current employment.

Michel David is Noema Pharma’s Vice President of CMC and Clinical Supply. His background includes pharmaceutical manufacturing, development, end-to-end supply-chain management and external-provider partnerships, with prior responsibilities at Roche. He is distinct from Montara physician David Michelson and Anzu investor David Michael; an image filename spelling Michael does not change the published Michel identity.

Sally Nixon is Noema Pharma’s Head of Operations. She has pharmaceutical-development and program-management experience spanning scientific, technical and business functions. Her earlier roles include senior program leadership at Certara and global medical-affairs project management at Roche.

Robert Lasser, also published as Rob Lasser, is Noema Pharma’s Chief Medical Officer. His CNS development experience includes clinical practice, research and biotechnology leadership. Previously he worked at Sage Therapeutics on zuranolone development and served as Chief Medical Officer at MedDay Pharmaceuticals. The company’s2023 appointment release uses Robert; its current directory uses Rob.

Michael Samar is Noema Pharma’s Chief Financial Officer. His earlier roles include CFO at Windgap Medical and Assembly Biosciences, finance leadership at Acorda/Biotie, Onyx, Agennix and Johnson & Johnson pharmaceutical research. He holds an MBA from Villanova University and a finance degree from Bryant University. His experience with other companies’ capital raises is distinct from Noema’s funding.

Volker Knappertz is Noema Pharma’s Executive Vice President of Research and Development. His career includes research leadership at Aurinia Pharmaceuticals and GW Pharmaceuticals, with experience advancing investigational medicines through development and regulatory review. Prior approvals mentioned in his biography concern other companies’ medicines and do not establish approval of Noema’s investigational candidates.

Ilise Lombardo is Noema Pharma’s Chief Executive Officer and a board director. She became CEO in June2023 after joining the board in2021. A physician and CNS drug-development executive, she co-founded Arvelle Therapeutics and served as its Chief Medical Officer before its acquisition by Angelini Pharma. Her earlier work includes Kriya Therapeutics, Pfizer, Forum and Axovant, and academic research at Columbia. She trained in psychiatry, neuroreceptor imaging and molecular genetics.

Martin Rosenzweig is publicly listed as an advisor to GreyMatter Capital. The manager’s own directory describes the professional background as: Behavioral Chief Medical Officer, Optum. This directory caption describes outside affiliations and experience; it does not establish current employment at those organizations or a GreyMatter executive position.

Devika Bhushan is publicly listed as an advisor to GreyMatter Capital. The manager’s own directory describes the professional background as: Pediatrician, public health leader, and former Acting Surgeon General of California. This directory caption describes outside affiliations and experience; it does not establish current employment at those organizations or a GreyMatter executive position.

Pete Shalek is publicly listed as an advisor to GreyMatter Capital. The manager’s own directory describes the professional background as: CPO AbleTo, Co-Founder & CEO, Joyable. This directory caption describes outside affiliations and experience; it does not establish current employment at those organizations or a GreyMatter executive position.

Giovanni Colella is publicly listed as an advisor to GreyMatter Capital. The manager’s own directory describes the professional background as: Co-founder, CEO Vanna Health, Ooda Health, Castlight Health; Co-founder, Brightline. This directory caption describes outside affiliations and experience; it does not establish current employment at those organizations or a GreyMatter executive position.

Tyler Norris is publicly listed as an advisor to GreyMatter Capital. The manager’s own directory describes the professional background as: Former CEO, Well Being Trust. This directory caption describes outside affiliations and experience; it does not establish current employment at those organizations or a GreyMatter executive position.

Kacie Kelly is publicly listed as an advisor to GreyMatter Capital. The manager’s own directory describes the professional background as: Chief Innovation Officer, Meadows Mental Health Institute (GreyMatter Policy Partner). This directory caption describes outside affiliations and experience; it does not establish current employment at those organizations or a GreyMatter executive position.

Richard Park is publicly listed as an advisor to GreyMatter Capital. The manager’s own directory describes the professional background as: Co-founder & former CEO, CityMD; Co-founder, Ascend Partners.. This directory caption describes outside affiliations and experience; it does not establish current employment at those organizations or a GreyMatter executive position.

Kelly Clark is publicly listed as an advisor to GreyMatter Capital. The manager’s own directory describes the professional background as: Former President, American Society of Addiction Medicine. This directory caption describes outside affiliations and experience; it does not establish current employment at those organizations or a GreyMatter executive position.

Margaret Laws is executive in residence at Hopelab and The Omidyar Group, supporting partners and investees and exploring mental-health innovation. She was Hopelab’s president and CEO from 2015 to 2025. At the California HealthCare Foundation she held public-financing and innovation leadership positions and launched its Health Innovation Fund. GreyMatter Capital also publicly lists her as an advisor; its older Hopelab CEO caption describes her former role.

Patrick Kennedy is publicly listed as an advisor to GreyMatter Capital. The manager’s own directory describes the professional background as: Leading mental health advocate and co-author of Mental Health Parity Act. This directory caption describes outside affiliations and experience; it does not establish current employment at those organizations or a GreyMatter executive position.

Martha Temple is publicly listed as an advisor to GreyMatter Capital. The manager’s own directory describes the professional background as: Former CEO, Optum Behavioral Health. This directory caption describes outside affiliations and experience; it does not establish current employment at those organizations or a GreyMatter executive position.

Dena Bravata is publicly listed as an advisor to GreyMatter Capital. The manager’s own directory describes the professional background as: Co-founder & former CMO, Lyra CMO, Castlight Health. This directory caption describes outside affiliations and experience; it does not establish current employment at those organizations or a GreyMatter executive position.

Venture Partner at GreyMatter Capital with experience in venture investing and healthcare technology. Her published biography describes strategic payer partnerships at Grow Therapy and earlier investing at General Catalyst, where she directed university-founder program Rough Draft Ventures. She previously supported platforms and portfolio development at Redpoint and Eniac Ventures. She earned a Harvard education master’s degree and studied psychology and communications at the University of Pennsylvania. Prior-employer investments are not attributed to GreyMatter.

Founding Partner of GreyMatter Capital. Before GreyMatter, he worked with mental-health startups and nonprofits, co-founded independent-work platform Prefer and served as its COO. Earlier he invested at Institutional Venture Partners and worked in technology investment banking at Qatalyst Partners. His current biography describes participation in San Francisco General Hospital Foundation’s behavioral-health transformation committee and earlier Well Being Trust advisory work. He studied economics and philosophy, politics and economics at the University of Pennsylvania.

Duncan Reece is named in Cohere Health’s dated primary SEC and/or issuer history. The role is retained as a historical or last-confirmed affiliation; current operating status and departure date are not established. Duncan’s name is misspelled Reese in the2021 SEC filing but issuer profile names Reece.

William H. Shrank is named in Cohere Health’s dated SEC filing. The role is retained as a historical or last-confirmed affiliation; current status and departure date are not established.

Kristen Carucci is named in Cohere Health’s dated SEC filing. The role is retained as a historical or last-confirmed affiliation; current status and departure date are not established.

Carrie Milby is named in Cohere Health’s dated SEC filing. The role is retained as a historical or last-confirmed affiliation; current status and departure date are not established.

Michael Greeley is identified as a Cohere Health director in the company’s May2025 SEC Form D. This source confirms a dated corporate board affiliation, not an individual cash investment or additional operating role. Michael Greeley is co-founder and general partner of Flare Capital Partners, previously founding general partner at Flybridge and earlier with Polaris Partners, Wasserstein Perella and Morgan Stanley. His own manager biography explicitly includes Cohere Health among board seats and lists a Williams chemistry BA and Harvard MBA.

David Barrett is identified as a Cohere Health director in the company’s May2025 SEC Form D. This source confirms a dated corporate board affiliation, not an individual cash investment or additional operating role. David (Dave) Barrett is Polaris’ senior advisory partner in Boston and a managing partner of Funds VI–IX and the Healthcare Technology Opportunities Fund. His healthcare AI interests include care-management platforms; Polaris confirms his Cohere Health board seat. Earlier operating experience includes Calico, Pure Atria/Rational and Lotus.

Julian Harris is identified as a Cohere Health director in the company’s May2025 SEC Form D. This source confirms a dated corporate board affiliation, not an individual cash investment or additional operating role.

Paul Johnson is an orthopedic spine surgeon with30+ years of experience who joined Cohere Health’s medical advisory board in April2025. The company identifies his participation in early spine clinical pathways and membership of the American Academy of Orthopaedic Surgeons and North American Spine Society. He advises clinical policies; this is not a corporate director or individual investment role.

Gary L. Gottlieb is executive chair of Cohere Health, explicitly identified by the company’s February2026 board-appointment release. Its2025 founders interview and SEC2025 filing corroborate his chair/director identity. Further career history is preserved if already recorded; no quoted chair role implies personal investment.

Mark Leenay joined Cohere Health’s board in February2026. A board-certified family-medicine/geriatrics physician, he previously served as COO of ChenMed, CEO of InHealth MD Alliance, and EVP/CMO of WellCare, and held executive positions at UnitedHealth Group. He earned his MD at Thomas Jefferson University.

Robert (Bob) Shepardson became Cohere Health CFO in October2024, with35+ years in healthcare and technology finance. The issuer cites his Princeton economics degree and Dartmouth Tuck MBA. SECMay2025 also names him executive officer and secretary.

Sohail Djariri was appointed Cohere Health chief revenue officer in April2026. Previously chief growth officer at Sagility, he spent17 years at Cognizant expanding its healthcare/life-sciences practice and also served in an executive role at Wipro.

Cathy Fackovec joined Cohere Health in January2026 to lead clinical and service operations. She has30+ years of clinical leadership and healthcare operations experience, with prior senior utilization-management/clinical-operations and market-president roles at naviHealth and Tomorrow Health.

Gigi Yuen-Reed, also published as Gigi Yuen, is Cohere Health’s chief data and AI officer, leading data management, data science, machine learning/AI and business intelligence. The company’s June2026 release confirms her PhD and recognition on its100 Women in AI2026 list.

Brian Covino is Cohere Health’s chief medical officer and an orthopedic surgeon with25+ years of clinical experience. Previously partner at Knoxville Orthopaedic Clinic and value-based care leader at OrthoTennessee, he earned a Harvard bachelor’s and Georgetown MD/MS, trained at Virginia and completed a Cleveland Clinic fellowship.

Siva Namasivayam co-founded Cohere Health and has served as CEO since2019. Previously a founding partner of SCIO Health Analytics, he has20+ years of healthcare technology and data experience. He holds a computer-science master’s from Pittsburgh and an MBA from Michigan.

Liana Nunziato is Senior Director of Commercial Strategy at Cohere Health, listed on its current growth client experience department page. The company recognizes this employee for cross-team collaboration and contributions to its healthcare technology and operations. A detailed education and prior-career biography was not published on this source.

Ryan Hebert is Client Support Specialist - L2 Triage at Cohere Health, listed on its current growth client experience department page. The company recognizes this employee for cross-team collaboration and contributions to its healthcare technology and operations. A detailed education and prior-career biography was not published on this source.

Nicole Saidai is Manager of Client & Provider Training and Development at Cohere Health, listed on its current growth client experience department page. The company recognizes this employee for cross-team collaboration and contributions to its healthcare technology and operations. A detailed education and prior-career biography was not published on this source.

Jayd Keener is Lead RN Reviewer at Cohere Health, listed on its current clinical operations strategy programs department page. The company recognizes this employee for cross-team collaboration and contributions to its healthcare technology and operations. A detailed education and prior-career biography was not published on this source.

Danielle Williams is RN Reviewer at Cohere Health, listed on its current clinical operations strategy programs department page. The company recognizes this employee for cross-team collaboration and contributions to its healthcare technology and operations. A detailed education and prior-career biography was not published on this source.

Ashleigh Magill is Associate Medical Director, Utilization Management at Cohere Health, listed on its current clinical operations strategy programs department page. The company recognizes this employee for cross-team collaboration and contributions to its healthcare technology and operations. A detailed education and prior-career biography was not published on this source.

Tina Hunt is Intake Specialist at Cohere Health, listed on its current clinical operations strategy programs department page. The company recognizes this employee for cross-team collaboration and contributions to its healthcare technology and operations. A detailed education and prior-career biography was not published on this source.

Sharika Gary is Real Time Analyst and Scheduler at Cohere Health, listed on its current clinical operations strategy programs department page. The company recognizes this employee for cross-team collaboration and contributions to its healthcare technology and operations. A detailed education and prior-career biography was not published on this source.

Josh Gallatin is Senior Strategic Operations Analyst at Cohere Health, listed on its current clinical operations strategy programs department page. The company recognizes this employee for cross-team collaboration and contributions to its healthcare technology and operations. A detailed education and prior-career biography was not published on this source.

Fatima Naqvi is Intake Specialist at Cohere Health, listed on its current clinical operations strategy programs department page. The company recognizes this employee for cross-team collaboration and contributions to its healthcare technology and operations. A detailed education and prior-career biography was not published on this source.

Daniel Torres is Clinical Training and Quality Specialist at Cohere Health, listed on its current clinical operations strategy programs department page. The company recognizes this employee for cross-team collaboration and contributions to its healthcare technology and operations. A detailed education and prior-career biography was not published on this source.

Emily Bliss is Medical Policy Writer at Cohere Health, listed on its current clinical operations strategy programs department page. The company recognizes this employee for cross-team collaboration and contributions to its healthcare technology and operations. A detailed education and prior-career biography was not published on this source.

Alaura Shefchik is Senior People Business Partner at Cohere Health, listed on its current ga department page. The company recognizes this employee for cross-team collaboration and contributions to its healthcare technology and operations. A detailed education and prior-career biography was not published on this source.

April Furlong is Compliance Project Manager at Cohere Health, listed on its current ga department page. The company recognizes this employee for cross-team collaboration and contributions to its healthcare technology and operations. A detailed education and prior-career biography was not published on this source.

Zoe Liao is Data Scientist II at Cohere Health, listed on its current technology department page. The company recognizes this employee for cross-team collaboration and contributions to its healthcare technology and operations. A detailed education and prior-career biography was not published on this source.

Tommy Sully is Senior Product Manager - AI Platform and Review AI at Cohere Health, listed on its current technology department page. The company recognizes this employee for cross-team collaboration and contributions to its healthcare technology and operations. A detailed education and prior-career biography was not published on this source.

Saikrishna Jaliparthy is Lead Software Engineer at Cohere Health, listed on its current technology department page. The company recognizes this employee for cross-team collaboration and contributions to its healthcare technology and operations. A detailed education and prior-career biography was not published on this source.

Richard Lu is Product Designer at Cohere Health, listed on its current technology department page. The company recognizes this employee for cross-team collaboration and contributions to its healthcare technology and operations. A detailed education and prior-career biography was not published on this source.

Kenji Fujita is Staff AI Platform Engineer at Cohere Health, listed on its current technology department page. The company recognizes this employee for cross-team collaboration and contributions to its healthcare technology and operations. A detailed education and prior-career biography was not published on this source.

Caterina Wang is Software Engineer II at Cohere Health, listed on its current technology department page. The company recognizes this employee for cross-team collaboration and contributions to its healthcare technology and operations. A detailed education and prior-career biography was not published on this source.

Anna Wang is Software Engineer II AI Platform at Cohere Health, listed on its current technology department page. The company recognizes this employee for cross-team collaboration and contributions to its healthcare technology and operations. A detailed education and prior-career biography was not published on this source. Principal at GreyMatter Capital with experience in private-market investing and startup operations. Previously Director of Strategic Partnerships at Blueprint Power, she worked on energy technology following its acquisition by BP. Earlier she invested in venture funds, growth equity and renewable-energy infrastructure at CPP Investments and worked in technology investment banking at TD Securities. She studied finance and strategy at McGill University. Her historical infrastructure investment totals are not GreyMatter capital.

Angela N. Wilson, DDS, joined the Kansas insurer’s board in 2018, chairs its dental advisory committee and serves on compensation and governance committees. Her individual biography describes her periodontal private practice at Southwind Periodontics; the general roster uses Edwards & Wilson Periodontics. Current role and career details are confirmed in the insurer’s own public biography. External affiliations are biographical context; no outside organization roles or personal investment checks are inferred. The insurer publishes a leadership image endpoint, but a matching binary portrait was not retrievable; no substitute photograph is used.

Jeffrey R. Thompson joined the Kansas insurer’s board in 2017 and chairs its audit/compliance committee. The individual biography identifies him as CFO of Velocity Flow Technologies, formerly Salina Vortex; the general roster retains the earlier company name. Current role and career details are confirmed in the insurer’s own public biography. External affiliations are biographical context; no outside organization roles or personal investment checks are inferred. The insurer publishes a leadership image endpoint, but a matching binary portrait was not retrievable; no substitute photograph is used.

Brittni Oehmke joined the Kansas insurer’s board in 2024 and serves on its investment committee and chairs its hospital advisory committee. She has led Hanover Hospital as CEO and administrator since August 2016. Current role and career details are confirmed in the insurer’s own public biography. External affiliations are biographical context; no outside organization roles or personal investment checks are inferred. The insurer publishes a leadership image endpoint, but a matching binary portrait was not retrievable; no substitute photograph is used.

Jeff D. Mullen joined the Kansas insurer’s board in 2018 and chairs its finance committee. He also serves on governance, investment and audit/compliance committees and is president of Ritchie Development. Current role and career details are confirmed in the insurer’s own public biography. External affiliations are biographical context; no outside organization roles or personal investment checks are inferred. The insurer publishes a leadership image endpoint, but a matching binary portrait was not retrievable; no substitute photograph is used.

Jena K. Lysen joined the Kansas insurer’s board in 2017 and chairs its compensation committee. Her individual biography identifies her as human-resources director at Martin, Pringle, Oliver, Wallace & Bauer. Current role and career details are confirmed in the insurer’s own public biography. External affiliations are biographical context; no outside organization roles or personal investment checks are inferred. The insurer publishes a leadership image endpoint, but a matching binary portrait was not retrievable; no substitute photograph is used.

Garrett Love joined the Kansas insurer’s board in 2023 and serves on finance, investment and audit/compliance committees. He founded Love Land & Cattle and is also publicly listed on the insurer foundation’s board. Current role and career details are confirmed in the insurer’s own public biography. External affiliations are biographical context; no outside organization roles or personal investment checks are inferred. The insurer publishes a leadership image endpoint, but a matching binary portrait was not retrievable; no substitute photograph is used.

James A. Klausman was elected to the Kansas insurer’s board in 2015 and serves on compensation and investment committees. He is CEO and co-founder of Midwest Health, a senior-living operator founded in 1977. Current role and career details are confirmed in the insurer’s own public biography. External affiliations are biographical context; no outside organization roles or personal investment checks are inferred. The insurer publishes a leadership image endpoint, but a matching binary portrait was not retrievable; no substitute photograph is used.

Megan L. Jones joined the Kansas insurer’s board in 2016 and is its current board chair. She chairs the governance and investment committees and founded Jones Advisory Group, where she develops clients’ financial strategies. Current role and career details are confirmed in the insurer’s own public biography. External affiliations are biographical context; no outside organization roles or personal investment checks are inferred. The insurer publishes a leadership image endpoint, but a matching binary portrait was not retrievable; no substitute photograph is used.

Rick C. Jackson was elected to the Kansas insurer’s board in 2015. He serves on governance, finance and audit/compliance committees, bringing banking and regulatory-compliance experience associated with Capitol Federal. Current role and career details are confirmed in the insurer’s own public biography. External affiliations are biographical context; no outside organization roles or personal investment checks are inferred. The insurer publishes a leadership image endpoint, but a matching binary portrait was not retrievable; no substitute photograph is used.

Amanda D. Huelskamp joined the Kansas insurer’s board in 2020 and serves on its compensation committee. The insurer’s biography identifies her as an HR business partner for enterprise initiatives at VSE Corp., with business and operations-management education at Wichita State University. Current role and career details are confirmed in the insurer’s own public biography. External affiliations are biographical context; no outside organization roles or personal investment checks are inferred. The insurer publishes a leadership image endpoint, but a matching binary portrait was not retrievable; no substitute photograph is used.

Leonard R. Hernandez joined the Kansas insurer’s board in 2012 and serves on its compensation committee. Its individual biography identifies him as a retired hospital executive, most recently president and CEO of Susan B. Allen Memorial Hospital. A broader board listing retains an older South Central Kansas Health affiliation. Current role and career details are confirmed in the insurer’s own public biography. External affiliations are biographical context; no outside organization roles or personal investment checks are inferred. The insurer publishes a leadership image endpoint, but a matching binary portrait was not retrievable; no substitute photograph is used.

James H. Gilbaugh III, MD, joined the Kansas insurer’s board in 2022 and serves on investment and medical advisory committees. He practices reproductive medicine and trained at Oregon Health Sciences University. Current role and career details are confirmed in the insurer’s own public biography. External affiliations are biographical context; no outside organization roles or personal investment checks are inferred. The insurer publishes a leadership image endpoint, but a matching binary portrait was not retrievable; no substitute photograph is used.

Gregory V. Binns joined the Kansas insurer’s board in 2016 and serves on finance and audit/compliance committees. His current biography describes him as retired vice chairman of First National Bank of Hutchinson. Current role and career details are confirmed in the insurer’s own public biography. External affiliations are biographical context; no outside organization roles or personal investment checks are inferred. The insurer publishes a leadership image endpoint, but a matching binary portrait was not retrievable; no substitute photograph is used.

Rick D. Baden joined the Kansas insurer’s board in 2020 and serves on its finance and audit/compliance committees. The insurer’s biography identifies him as Watco’s executive vice president and CFO and a certified public accountant. Current role and career details are confirmed in the insurer’s own public biography. External affiliations are biographical context; no outside organization roles or personal investment checks are inferred. The insurer publishes a leadership image endpoint, but a matching binary portrait was not retrievable; no substitute photograph is used.

Sunee Mickle leads government and community relations at Blue Cross and Blue Shield of Kansas, holding the vice president appointment since April 2018. She joined in 2007 after policy and healthcare-industry roles. She studied public health at Rutgers and law at Washburn University. Current role and career details are confirmed in the insurer’s own public biography. External affiliations are biographical context; no outside organization roles or personal investment checks are inferred. The authentic named insurer-blog photograph is historical, not claimed as a newly taken portrait.

Treena Mason is executive vice president and chief sales officer at Blue Cross and Blue Shield of Kansas, holding the current appointment since 2023. She joined in 1997 and progressed through regional sales, marketing and operational leadership. Her publicly listed outside service includes the Wichita Chamber of Commerce and Wichita State University’s business-school advisory board. Current role and career details are confirmed in the insurer’s own public biography. External affiliations are biographical context; no outside organization roles or personal investment checks are inferred. The authentic named insurer-blog photograph is historical, not claimed as a newly taken portrait.

Matt Langdon leads information technology as vice president and CIO of Blue Cross and Blue Shield of Kansas, a role held since 2020. He joined the insurer in 1997 and previously worked in enterprise architecture and systems analysis. He earned a business-administration degree at Washburn University. Current role and career details are confirmed in the insurer’s own public biography. External affiliations are biographical context; no outside organization roles or personal investment checks are inferred. The insurer publishes a leadership image endpoint, but a matching binary portrait was not retrievable; no substitute photograph is used.

Raelene Knolla, DO, was appointed senior vice president and chief medical officer at Blue Cross and Blue Shield of Kansas in 2025. Her prior roles include Medrina, Blue Cross and Blue Shield of Kansas City and Humana. She trained in osteopathic medicine and healthcare management. Current role and career details are confirmed in the insurer’s own public biography. External affiliations are biographical context; no outside organization roles or personal investment checks are inferred. The insurer publishes a leadership image endpoint, but a matching binary portrait was not retrievable; no substitute photograph is used.

Mandy Harris became chief of staff at Blue Cross and Blue Shield of Kansas in 2024. She began with the insurer as a New Venture Initiative intern, later working on enterprise risk, strategy and analytics. She studied accounting at the University of Idaho and earned an MBA at the University of Kansas. Current role and career details are confirmed in the insurer’s own public biography. External affiliations are biographical context; no outside organization roles or personal investment checks are inferred. The insurer publishes a leadership image endpoint, but a matching binary portrait was not retrievable; no substitute photograph is used.

Holly Graves is vice president of operations and COO of government programs at Blue Cross and Blue Shield of Kansas, holding that role since 2020. She joined as a claims examiner in 1985 and subsequently led service and operational teams, including administration of federal healthcare programs. Current role and career details are confirmed in the insurer’s own public biography. External affiliations are biographical context; no outside organization roles or personal investment checks are inferred. The insurer publishes a leadership image endpoint, but a matching binary portrait was not retrievable; no substitute photograph is used.

Mike Gerrish leads marketing and customer experience at Blue Cross and Blue Shield of Kansas, having joined in 2020. His earlier experience includes Wellmark Blue Cross Blue Shield, Payless ShoeSource and Discover Financial Services. He studied communications at Western Illinois University. Current role and career details are confirmed in the insurer’s own public biography. External affiliations are biographical context; no outside organization roles or personal investment checks are inferred. The insurer publishes a leadership image endpoint, but a matching binary portrait was not retrievable; no substitute photograph is used.

Nicki Flanagan leads human resources at Blue Cross and Blue Shield of Kansas as senior vice president and chief human resources officer, with the senior appointment confirmed since 2023. She joined the insurer in 2016, following operational and HR leadership at The Home Depot’s supply-chain business. Current role and career details are confirmed in the insurer’s own public biography. External affiliations are biographical context; no outside organization roles or personal investment checks are inferred. The insurer publishes a leadership image endpoint, but a matching binary portrait was not retrievable; no substitute photograph is used.

Clay Britton is senior vice president, general counsel and corporate secretary of Blue Cross and Blue Shield of Kansas. He joined in December 2021 and received the senior vice president appointment in 2023. His prior work includes counsel to Kansas Governor Laura Kelly, federal prosecution and private legal practice. He studied law at the University of Kansas. Current role and career details are confirmed in the insurer’s own public biography. External affiliations are biographical context; no outside organization roles or personal investment checks are inferred. The insurer publishes a leadership image endpoint, but a matching binary portrait was not retrievable; no substitute photograph is used.

Jeff Bergman is the Kansas insurer’s senior vice president and CFO, overseeing accounting, actuarial work, risk management, underwriting, strategic investments and vendor management. He joined the organization in 2007 as an actuarial analyst and became senior vice president in 2023. Current role and career details are confirmed in the insurer’s own public biography. External affiliations are biographical context; no outside organization roles or personal investment checks are inferred. The insurer publishes a leadership image endpoint, but a matching binary portrait was not retrievable; no substitute photograph is used.

Staci Berger leads provider-network solutions at Blue Cross and Blue Shield of Kansas, with the current appointment confirmed since 2024. Her work involves network programs, provider collaboration and access to care. Her earlier healthcare experience includes UnitedHealthcare and Humana. Current role and career details are confirmed in the insurer’s own public biography. External affiliations are biographical context; no outside organization roles or personal investment checks are inferred. The insurer publishes a leadership image endpoint, but a matching binary portrait was not retrievable; no substitute photograph is used.

Matthew D. All leads Blue Cross and Blue Shield of Kansas as president and CEO, a position held since April 2018. He joined the insurer in 2006 and previously served as its general counsel. His earlier public-service work included Kansas insurance regulation and legal counsel to Governor Kathleen Sebelius. He earned his undergraduate degree at the University of Kansas and law degree at Yale. Current role and career details are confirmed in the insurer’s own public biography. External affiliations are biographical context; no outside organization roles or personal investment checks are inferred. The authentic named insurer-blog photograph is historical, not claimed as a newly taken portrait.

Dennis Moreno leads manufacturing and operations at MiRus. His engineering background spans aerospace projects, robotics and medical-device development; his current individual biography and leadership directory agree on this operational role despite an older engineering title in the URL.

Wayne Gray leads orthopedic engineering at MiRus. His career includes research and development for orthopedic, spinal and extremity products at Zimmer, Abbott, Exactech and RTI.

Pam Cowart leads clinical affairs and compliance at MiRus. She combines cardiovascular nursing experience with medical-device clinical work, including heart-failure programs at CardioMEMS.

Jordan Bauman leads quality and regulatory affairs at MiRus. His experience spans medical-device development, regulatory submissions, reimbursement and commercialization for cardiovascular, orthopedic and spinal products.

Mahesh Krishnan is Chief Commercial Officer at MiRus. His health care experience includes orthopedic imaging at Carestream, spine products at DePuy Synthes, and marketing, sales and operating roles at Philips and Alliance Healthcare.

David Toney is MiRus’s Chief Financial Officer, joining in February 2022. His previous work included finance and operational leadership at Mohawk and finance, accounting and product-marketing roles at Seagate Technology and Chiaro Networks.

Noah Roth is MiRus’s Chief Operating Officer. He has a background in engineering and law and led development of the MoRe alloy at Icon Interventional Systems. His earlier medical-device work included embolic and vascular technology.

Interventional cardiologist and medical-device entrepreneur Jay Yadav founded MiRus and serves as CEO. Earlier ventures included CardioMEMS and Angioguard. His own biography describes work on stroke and heart-failure treatments, scientific publications and medical-device inventions. MiRus’s current focus combines novel implant alloys with orthopedic and cardiovascular technology.

Co-founder of Kvantify. The issuer announced in August 2025 that he stepped back from his operational role and remained a shareholder and supporter; no current CEO role is asserted. Kvantify’s filed2024 annualreport gives his full name as Hans Henrik Hernesniemi Knudsen and lists him as managing director and a board member when approved in June2025.

Søren Galatius is published by Kvantify as an external Scientific Advisory Board member. Columbia mathematics professor researching algebraic topology and geometry; holds an Aarhus mathematics doctorate.

Ove Christiansen is published by Kvantify as an external Scientific Advisory Board member. Aarhus theoretical-chemistry professor researching quantum and computational molecular predictions, with an Aarhus theoretical-chemistry doctorate.

Niels Pørksen is published by Kvantify as an external Scientific Advisory Board member. LeanBio founder and physician with an Aarhus medical doctorate and PhD. Previously held Sanofi and Eli Lilly leadership responsibilities in diabetes and obesity therapeutics.

Morten Kjærgaard is published by Kvantify as an external Scientific Advisory Board member. Niels Bohr Institute associate professor researching quantum information, devices and experimental computation; holds a Copenhagen quantum-device-physics doctorate.

Martin Ulmschneider is published by Kvantify as an external Scientific Advisory Board member. King’s College London computational-chemistry professor researching peptides, proteins and membrane interactions; holds a DPhil focused on membrane-protein simulations.

Kasper G. Larsen is published by Kvantify as an external Scientific Advisory Board member. Aarhus computer-science professor heading its Algorithms, Data and Artificial Intelligence section, researching algorithms and theoretical machine learning; earned his doctorate at Aarhus.

Frank Jensen is published by Kvantify as an external Scientific Advisory Board member. Aarhus chemistry associate professor researching quantum mechanics and computational molecular modelling; holds a UCLA chemistry doctorate.

David Gloriam is published by Kvantify as an external Scientific Advisory Board member. Copenhagen pharmacology researcher studying computational receptor biology and G protein-coupled receptors; holds an Uppsala pharmacology and bioinformatics doctorate.

Caterina Vigliar is published by Kvantify as an external Scientific Advisory Board member. DTU assistant professor studying integrated quantum photonics, high-dimensional encoding and measurement-based quantum computation; holds a Bristol doctorate.

Albert J. Kooistra is published by Kvantify as an external Scientific Advisory Board member. Copenhagen associate professor studying data science for drug design; earned a computational medicinal-chemistry doctorate at Vrije Universiteit Amsterdam.

Tobias Holm Jerichow is published by Kvantify as CFO. Finance executive responsible for financial planning, infrastructure and fundraising support, drawing on finance and consulting experience. The public biography does not specify educational qualifications.

Nikolaj Thomas Zinner is published by Kvantify as Co-founder and CSO. Aarhus physics professor and quantum-technology researcher with a physics doctorate, working on quantum information and physics-based modelling and leading research collaborations.

Jörg Weiser is published by Kvantify as Executive Chairperson. Computational molecular-research executive who built businesses in Europe and Asia. Holds a Göttingen organic-chemistry doctorate and previously led Schrödinger international operations. Delphinus Venture Capital’s current portfolio directory additionally publishes an interim CEO capacity at Kvantify; Kvantify’s own current directory publishes Executive Chairperson.

David Siebert is published by Kvantify as SVP, Global Head of Business Development. Scientific business-development executive with previous roles at Schrödinger, Syngene and Avantor. Holds a TU Wien medicinal-chemistry doctorate and a Zürich International Business School MBA.

Christina Krogsgård Nielsen is published by Kvantify as COO. Operations executive with an Aarhus nanoscience doctorate and seven years at McKinsey, where she served as an engagement manager.

Casper Kirkegaard is published by Kvantify as EVP, Head of Engineering. Engineering leader and applied-science software specialist with a geophysics doctorate from Aarhus University.

Allan Grønlund is published by Kvantify as Co-founder and CTO. Computer scientist specialising in machine learning and applied algorithms; earned an Aarhus computer-science doctorate and worked across academic and industrial applications of mathematical models.

Co-founder and legal manager of Hesperia Capital. His published background spans lending, financial advice and investing across businesses. He has advised entrepreneurs, family companies and boards on strategic planning, acquisitions, divestitures, buyouts and recapitalizations, and combines transaction experience with capital and operating advice.

Co-founder and legal manager of Hesperia Capital. His own biography describes experience in growth investing, corporate development, startup finance and investment banking. He has worked across Internet of Things businesses and emphasizes operational systems, financial infrastructure and the integration of hardware, software and cloud services.

Jason Pritzker is affiliated with The Pritzker Organization and co-founded 53 Stations, according to the manager’s advisor page.

Aaron Libbey is Chief Growth Officer at Altana and previously worked at Palantir, according to the current fund announcement.

Neha Kumar brings payer and product experience at Datavant, where the current fund announcement identifies her as SVP of Product.

Vinod Mitta, MD, brings medical and healthcare policy experience. The manager page identifies Medical Officer experience at the Center for Medicare and Medicaid Innovation; the current fund announcement identifies him as SVP of Policy and Strategy at Formation Bio.

Jesse Horowitz is Chief Product Officer at Oscar Health, according to the manager’s team page and fund announcement.

Serkan Piantino co-founded Facebook AI and was VP of Product at Reddit.

The manager identifies prior experience as Chief Operating Officer at Maycomb Capital.

John Loser co-founded Floating Point with Edward Segel. They previously built trading systems at Bridgewater and helped build Oscar Health, bringing public-market investment and company operating experience to the firm.

Edward (Eddie) Segel co-founded Floating Point with John Loser after working together at Bridgewater and on the founding team of Oscar Health, where they led product, data and risk.

Published as an EIC Fund company board representative; this is a portfolio-company governance role, not employment by the EIC Fund or membership of its own board. Atlantic Bridge’s March22,2025 published directory identifies Osman Kent as Venture Partner. This is a dated published affiliation; current tenure is not independently confirmed by the redesigned live site. Osman is a serial technology and media entrepreneur best known as the founder and CEO of 3Dlabs - at one time one of the fastest growing NASDAQ companies in Silicon Valley. 3Dlabs is a fabless chip company whose products were used in the making of films like the Titanic and The Matrix and helped pioneer the 3D graphics revolution on the PC. Osman is a Fellow of the Royal Society of Arts in the UK, has a First Class degree in Computer Science and Electronics Engineering from University of Birmingham (UK) and is the inventor of numerous patents in the field of computing and graphics

Published as an EIC Fund company board representative; this is a portfolio-company governance role, not employment by the EIC Fund or membership of its own board.

Published as an EIC Fund company board representative; this is a portfolio-company governance role, not employment by the EIC Fund or membership of its own board.

Published as an EIC Fund company board representative; this is a portfolio-company governance role, not employment by the EIC Fund or membership of its own board.

Published as an EIC Fund company board representative; this is a portfolio-company governance role, not employment by the EIC Fund or membership of its own board.

Published as an EIC Fund company board representative; this is a portfolio-company governance role, not employment by the EIC Fund or membership of its own board.

Published as an EIC Fund company board representative; this is a portfolio-company governance role, not employment by the EIC Fund or membership of its own board.

Published as an EIC Fund company board representative; this is a portfolio-company governance role, not employment by the EIC Fund or membership of its own board.

Published as an EIC Fund company board representative; this is a portfolio-company governance role, not employment by the EIC Fund or membership of its own board.

Published as an EIC Fund company board representative; this is a portfolio-company governance role, not employment by the EIC Fund or membership of its own board.

Published as an EIC Fund company board representative; this is a portfolio-company governance role, not employment by the EIC Fund or membership of its own board.

Butterfly’s main team page publishes Tanya Horowitz, while its fund disclosure identifies the same partner as Tanya Marvin-Horowitz. She is Stockholm based.

Atlantic Bridge’s March22,2025 published directory identifies Helen McBreen as Partner. This is a dated published affiliation; current tenure is not independently confirmed by the redesigned live site. Helen joined Atlantic Bridge in 2015 on our University Bridge Fund. At Atlantic Bridge, Helen leads investing in early stage deeptech companies. With a strong track record built over 15 years, Helen has successfully sourced and financed over 40 deep tech ventures including notable Irish companies: Neurent Medical, Equal1, Siren, Output Sports, Proverum Medical, Plasmabound and Manna. Companies from Atlantic Bridge’s early stage portfolio have to date raised over €700m and continue to grow and scale globally. Helen is on the board of many venture backed companies and chairs the Governance Committee of IPIC , a Science Foundation Ireland Centre for photonics. Helen is both mentor and advisor to organisations including Knowledge Transfer Ireland, IVCA, UCD VentureLaunch, Start100 and is a prior VP at TechTour. Passionate about encouraging young people’s involvement in STEM, Helen is board member of the education focused non-profit, Kinia, and is a judge at the BT Young Scientist and Technology Competition. Helen is listed as one of the Top 100 Women in STEM in Ireland and is a Kauffman Fellow. Helen was awarded a 1st Class Hons. Electronic Engineering Degree (UCD) and a PhD (The University of Edinburgh) in the area of AI based conversational agents and multimodal interfaces.

Bianka Vargas serves on Horizon Mutual Holdings, Inc.’s board according to the year-end2025 primary regulator filing certifiedMay26,2026. Administration professional in the comptroller’s office of the Elizabeth Board of Education. This is a corporate governance affiliation, not a claim that every director is a venture investment employee or personally funded the parent’s portfolio. Outside positions are qualified to that dated primary filing.

Donna Smyth serves on Horizon Mutual Holdings, Inc.’s board according to the year-end2025 primary regulator filing certifiedMay26,2026. Paralegal at the Law Offices of Nicholas P. Scutari; appointedDecember2025 per primaryfiling. This is a corporate governance affiliation, not a claim that every director is a venture investment employee or personally funded the parent’s portfolio. Outside positions are qualified to that dated primary filing.

Ninfa Saunders serves on Horizon Mutual Holdings, Inc.’s board according to the year-end2025 primary regulator filing certifiedMay26,2026. Former president and chief executive of Navicent Health. This is a corporate governance affiliation, not a claim that every director is a venture investment employee or personally funded the parent’s portfolio. Outside positions are qualified to that dated primary filing.

Joseph Roberts serves on Horizon Mutual Holdings, Inc.’s board according to the year-end2025 primary regulator filing certifiedMay26,2026. Former speaker of the New Jersey General Assembly. This is a corporate governance affiliation, not a claim that every director is a venture investment employee or personally funded the parent’s portfolio. Outside positions are qualified to that dated primary filing.

Cassandra Santos serves on Horizon Mutual Holdings, Inc.’s board according to the year-end2025 primary regulator filing certifiedMay26,2026. Chief technology officer of Caliber Collision, as identified in the dated filing. This is a corporate governance affiliation, not a claim that every director is a venture investment employee or personally funded the parent’s portfolio. Outside positions are qualified to that dated primary filing.

Vikki Pryor serves on Horizon Mutual Holdings, Inc.’s board according to the year-end2025 primary regulator filing certifiedMay26,2026. Founder, managing principal and president of Change Create Transform LLC. This is a corporate governance affiliation, not a claim that every director is a venture investment employee or personally funded the parent’s portfolio. Outside positions are qualified to that dated primary filing.

Diana Nole serves on Horizon Mutual Holdings, Inc.’s board according to the year-end2025 primary regulator filing certifiedMay26,2026. Former corporate vice president at Nuance, a healthcare speech and AI technology business. This is a corporate governance affiliation, not a claim that every director is a venture investment employee or personally funded the parent’s portfolio. Outside positions are qualified to that dated primary filing.

James Mitchell Jr. serves on Horizon Mutual Holdings, Inc.’s board according to the year-end2025 primary regulator filing certifiedMay26,2026. Founder of JMJ Advisors. This is a corporate governance affiliation, not a claim that every director is a venture investment employee or personally funded the parent’s portfolio. Outside positions are qualified to that dated primary filing.

Co-founder and Chief Technology Officer of Multiscale Technologies, confirmed by his April 30 and May 4, 2026 company publications. Leads development of industrial AI software connecting materials, process and manufacturing expertise with digital twins and AI agents.

Co-founder and CEO of Multiscale AI, confirmed by the company’s May 12, 2026 announcement. Georgia Tech faculty member whose research spans materials engineering, mechanics, manufacturing and data science, translating physics-informed AI research into industrial technology.

Co-founder of OmniTier. The company’s own April 18, 2023 product announcement identifies him as CEO and co-founder; the enduring founder relationship is recorded here because its current website does not publish a current executive roster.

Carlos Medina serves on Horizon Mutual Holdings, Inc.’s board according to the year-end2025 primary regulator filing certifiedMay26,2026. Chairman of the Statewide Hispanic Chamber of Commerce and president of Robinson Aerial Surveys, Inc., as identified in the dated filing. This is a corporate governance affiliation, not a claim that every director is a venture investment employee or personally funded the parent’s portfolio. Outside positions are qualified to that dated primary filing.

Kelly Stewart Maer serves on Horizon Mutual Holdings, Inc.’s board according to the year-end2025 primary regulator filing certifiedMay26,2026. Former director of public affairs at Capital Health System. This is a corporate governance affiliation, not a claim that every director is a venture investment employee or personally funded the parent’s portfolio. Outside positions are qualified to that dated primary filing.

Stephanie Lagos serves on Horizon Mutual Holdings, Inc.’s board according to the year-end2025 primary regulator filing certifiedMay26,2026. Former chief of staff to the First Lady of New Jersey; appointed to Horizon board inDecember2025 per primaryfiling. This is a corporate governance affiliation, not a claim that every director is a venture investment employee or personally funded the parent’s portfolio. Outside positions are qualified to that dated primary filing.

Joseph Kyrillos serves on Horizon Mutual Holdings, Inc.’s board according to the year-end2025 primary regulator filing certifiedMay26,2026. Former New Jersey state senator and principal of SK Partners. This is a corporate governance affiliation, not a claim that every director is a venture investment employee or personally funded the parent’s portfolio. Outside positions are qualified to that dated primary filing.

Brian Kinkead serves on Horizon Mutual Holdings, Inc.’s board according to the year-end2025 primary regulator filing certifiedMay26,2026. Retired vice chairman of the Global Healthcare Group at Bank of America Merrill Lynch. This is a corporate governance affiliation, not a claim that every director is a venture investment employee or personally funded the parent’s portfolio. Outside positions are qualified to that dated primary filing.

Paul Juliano serves on Horizon Mutual Holdings, Inc.’s board according to the year-end2025 primary regulator filing certifiedMay26,2026. Former president and CEO of the New Jersey Sports and Exposition Authority. This is a corporate governance affiliation, not a claim that every director is a venture investment employee or personally funded the parent’s portfolio. Outside positions are qualified to that dated primary filing.

Leonard Feld serves on Horizon Mutual Holdings, Inc.’s board according to the year-end2025 primary regulator filing certifiedMay26,2026. President of Leonard G. Feld, MD, LLC and retired president of Pediatric Specialists of America. This is a corporate governance affiliation, not a claim that every director is a venture investment employee or personally funded the parent’s portfolio. Outside positions are qualified to that dated primary filing.

Leonard Coleman serves on Horizon Mutual Holdings, Inc.’s board according to the year-end2025 primary regulator filing certifiedMay26,2026. Former president of the National League of Professional Baseball Clubs. This is a corporate governance affiliation, not a claim that every director is a venture investment employee or personally funded the parent’s portfolio. Outside positions are qualified to that dated primary filing.

Ralph Caputo serves on Horizon Mutual Holdings, Inc.’s board according to the year-end2025 primary regulator filing certifiedMay26,2026. Former New Jersey Assemblyman. This is a corporate governance affiliation, not a claim that every director is a venture investment employee or personally funded the parent’s portfolio. Outside positions are qualified to that dated primary filing.

Todd Brown serves on Horizon Mutual Holdings, Inc.’s board according to the year-end2025 primary regulator filing certifiedMay26,2026. Lead independent director of Horizon Mutual Holdings; earlier vice chairman of ShoreBank Corporation, now retired from that outside job. This is a corporate governance affiliation, not a claim that every director is a venture investment employee or personally funded the parent’s portfolio. Outside positions are qualified to that dated primary filing.

Geoffrey Arlen serves on Horizon Mutual Holdings, Inc.’s board according to the year-end2025 primary regulator filing certifiedMay26,2026. Founder of Arlen Law Firm, LLC. This is a corporate governance affiliation, not a claim that every director is a venture investment employee or personally funded the parent’s portfolio. Outside positions are qualified to that dated primary filing.

Douglas Falduto is vice president, administration and chief security officer at Horizon Mutual Holdings, Inc., according to the dated2025parentreport. Administration and enterprise security leader named in the primary parent employee disclosure. The primary source is the year-end2025 information statement certifiedMay26,2026; later employment changes are not inferred from older subsidiary biographies.

Kenny Kan is vice president and chief actuary at Horizon Mutual Holdings, Inc., according to the dated2025parentreport. Actuarial leader named in the primary parent employee disclosure. The primary source is the year-end2025 information statement certifiedMay26,2026; later employment changes are not inferred from older subsidiary biographies.

Alison Banks-Moore is vice president and chief diversity officer at Horizon Mutual Holdings, Inc., according to the dated2025parentreport. Corporate diversity leader named in the primary parent employee disclosure. The primary source is the year-end2025 information statement certifiedMay26,2026; later employment changes are not inferred from older subsidiary biographies.

Joseph Albano is vice president, commercial and specialty markets at Horizon Mutual Holdings, Inc., according to the dated2025parentreport. Commercial and specialty insurance markets leader named in the primary parent employee disclosure. The primary source is the year-end2025 information statement certifiedMay26,2026; later employment changes are not inferred from older subsidiary biographies.

Jamie Reedy is senior vice president, health solutions at Horizon Mutual Holdings, Inc., according to the dated2025parentreport. Healthcare solutions leader named in the primary parent officer/employee disclosure. The primary source is the year-end2025 information statement certifiedMay26,2026; later employment changes are not inferred from older subsidiary biographies.

Jennifer Velez is executive vice president, health and network solutions at Horizon Mutual Holdings, Inc., according to the dated2025parentreport. Oversees network and care delivery solutions, value-based programs, clinical operations, pharmacy, behavioral health, and clinical analytics and medical economics. The primary source is the year-end2025 information statement certifiedMay26,2026; later employment changes are not inferred from older subsidiary biographies.

Aisha Thomas-Petit is senior vice president and chief human resources officer at Horizon Mutual Holdings, Inc., according to the dated2025parentreport. Leads workforce strategy, talent acquisition, organizational development, compensation, employee relations, leadership development and training. The primary source is the year-end2025 information statement certifiedMay26,2026; later employment changes are not inferred from older subsidiary biographies.

Timothy Susanin is senior vice president, audit, risk and compliance at Horizon Mutual Holdings, Inc., according to the dated2025parentreport. Leads internal audit, risk assessment, controls management and compliance. The primary source is the year-end2025 information statement certifiedMay26,2026; later employment changes are not inferred from older subsidiary biographies.

Heather Staples is executive vice president, enterprise business and technology solutions and operations at Horizon Mutual Holdings, Inc., according to the dated2025parentreport. Oversees planning, development and delivery of IT applications and infrastructure, technology operations and enterprise service initiatives. The primary source is the year-end2025 information statement certifiedMay26,2026; later employment changes are not inferred from older subsidiary biographies.

David Rosenberg is executive vice president and chief financial officer at Horizon Mutual Holdings, Inc., according to the dated2025parentreport. Manages the financial risks of the enterprise and its financial reporting; insurance reserve and corporate capital values are distinct from venture fund fundraising. The primary source is the year-end2025 information statement certifiedMay26,2026; later employment changes are not inferred from older subsidiary biographies.

Debra Ann Rittenour is senior vice president, government programs at Horizon Mutual Holdings, Inc., according to the dated2025parentreport. Leads Medicare Advantage, managed Medicaid, dual special needs, long-term services and supports, and Medicare supplemental plans. The parent filing explicitly records her assumption of the Government Programs role onApril1,2025. The primary source is the year-end2025 information statement certifiedMay26,2026; later employment changes are not inferred from older subsidiary biographies.

Nicholas Peterson is executive vice president, general counsel and secretary at Horizon Mutual Holdings, Inc., according to the dated2025parentreport. Manages enterprise legal affairs and regulatory mandates, provides legal advice, and serves as secretary of the board. He certified the parent’s2025regulatoryinformation statement onMay26,2026. The primary source is the year-end2025 information statement certifiedMay26,2026; later employment changes are not inferred from older subsidiary biographies.

Christopher Lepre is executive vice president, commercial business at Horizon Mutual Holdings, Inc., according to the dated2025parentreport. Oversees sales and account management across medical, pharmacy, dental, vision, life, disability and stop-loss insurance markets. The primary source is the year-end2025 information statement certifiedMay26,2026; later employment changes are not inferred from older subsidiary biographies.

Ulises Diaz is senior vice president, government and community affairs at Horizon Mutual Holdings, Inc., according to the dated2025parentreport. Leads government advocacy and community affairs and oversees the Horizon Foundation for New Jersey. The primary source is the year-end2025 information statement certifiedMay26,2026; later employment changes are not inferred from older subsidiary biographies.

Mark Barnard is former executive vice president, government programs and operations at Horizon Mutual Holdings, Inc., in a historical affiliation. The primary filing explicitly records his separation on April1,2025; his inclusion in the officer exhibit is historical and not treated as a current job. The primary source is the year-end2025 information statement certifiedMay26,2026; later employment changes are not inferred from older subsidiary biographies.

Patrick Aylward is senior vice president, strategy, marketing and communications at Horizon Mutual Holdings, Inc., according to the dated2025parentreport. Oversees corporate strategy, marketing and communications and serves as chief of staff to the president and CEO. The primary source is the year-end2025 information statement certifiedMay26,2026; later employment changes are not inferred from older subsidiary biographies.

Gary St. Hilaire is chairman, president and chief executive officer at Horizon Mutual Holdings, Inc., according to the dated2025parentreport. Manages the performance and strategy of the whole mutual holding company system. The primary source is the year-end2025 information statement certifiedMay26,2026; later employment changes are not inferred from older subsidiary biographies.

Judy Park is Managing Director of Investments at Fiore Ventures, confirmed by her own current promotion announcement reposted by the firm and Stanford’s current investment-committee directory. Her prior investing experience includes Owl Ventures and Bain Capital Double Impact. She studied at Harvard and Stanford’s Graduate School of Business. The firm’s current investment focus includes health care AI and family mental health; older biographies describing her as a strategic adviser are retained as historical context.

John Bailey advises Fiore Ventures on investments and strategy in behavioral health and related fields. His background includes domestic policy work in the White House, the US Department of Commerce, the Gates Foundation and the Chan Zuckerberg Initiative. He also advises organizations working on AI governance, education and public-interest technology. Fiore’s current public profile continues to identify him with the firm.

Carrie Walton Penner founded Fiore Ventures to invest in businesses and initiatives expanding mental-health access. Her background includes education research, evaluation and philanthropy. She is also a Denver Broncos co-owner and serves on the Walton Family Foundation board. Those personal and philanthropic affiliations are distinct from Fiore’s institutional investments.

Youth digital-safety, media and education specialist, author and podcast producer. His ownOctober2025 retrospective identifies him as formerBeMe chiefyouthprivacypolicyofficer and producer ofBeingMe teenmentalhealthpodcast, with morethan25years inchildren’smedia andeducationaltechnology. His currentownsite suppliesauthenticidentity/portrait.

Healthcare commercial executive who led BeMe commercial strategy fromlate2023 through its sale toHazel. Her own published account confirms the appointment; primary partner biography names her formerBeMeCCO and describes currentSomethingsCCO service, priorPapa client-success leadership and25years inhealthcare. ExactindependentBeMe roleishistorical.

David Brillembourg Jr. is the founder of Dune Ventures. Orbit Technologies’ November2023 issuer release identifies him as the firm’s founder; his own current professional profile links dune.ventures and describes investing in exceptional people at the earliest stages. His own posts describe continued backing of Pim de Witte/General Intuition and co-leading Joon’s2023 financing. Dune Fund II’s June2026 SEC filing identifies David Brillembourg as executive officer and managing member of the GP’s GP. His professional profile lists NYU Stern education; no completed degree is inferred. He is distinct from the older hospitality entrepreneur David Brillembourg Capriles and other same-name professionals.

Founder and CEO of Behavioral Health Tech, a community and events organization connecting behavioral-health providers, payors, technology businesses and investors. Its current own speaker biography supplies her identity and portrait. BeMe’s2021issuer release includes her in its combined board/adviser list; no individual director title or current acquired-company position is inferred.

Healthcare venture investor and co-founder of Flare Capital Partners. Current Red Cell Partners biography names him senior healthcare adviser and notes continued Flare executive-partner advisory work. Previously led North Bridge’s healthcare investment practice. BeMe’s issuer named him in its combined board/adviser list in2021, without assigning an individual director seat.

Healthcare physician and entrepreneur named among BeMe’s founders in the issuer’s2021launch announcement. The same source describes prior leadership of Merit Behavioral and Alere. Founder history is recorded without inferring a current BeMe management role.

John Roche is non-executive director of listed investment company Syncona Limited. Guernsey-based chartered accountant who joined Syncona Limited’s board in October 2024. Previously a PwC partner, Guernsey managing partner and Channel Islands capital markets practice leader.

Behavioral-health entrepreneur named among BeMe’s founders in the issuer’s2021launch. Previously co-founded and led myStrength, acquired by Livongo. Current WellPower primary board directory identifies him as founder of Coella Partners; founder history is not treated as a current BeMe staff appointment.

Gian Piero Reverberi is non-executive director of listed investment company Syncona Limited. Pharmaceutical commercial executive previously at Ferring through April 2026, Vanda Pharmaceuticals, Shire and Eli Lilly.

Norman Crighton is non-executive director of listed investment company Syncona Limited. Investment company specialist with experience in banking, fund management and listed-board governance. His work includes closed-ended investment companies and IPO structuring.

Marketing and commercial executive who joined BeMe as chief business officer inJuly2022. The issuer biography describes prior chief marketing officer service at Twin Health and a decade at Facebook including Messenger, Messenger Kids and community operations. Her published BeMe role is historical, without an inferred current appointment.

Julie Cherrington is non-executive director of listed investment company Syncona Limited. Biotechnology executive experienced in oncology development and company leadership across North America and Australia. Trained in microbiology and immunology at Minnesota and Stanford. Julie Cherrington is venture partner - usa at Brandon Capital. Her2022 Brandon venture-partner appointment adds extensive oncology and biotechnology operating experience. Her career includes leadership at QUE, Arch, Revitope, Zenith and Pathway, with earlier research management at SUGEN and Gilead. Existing Syncona directorships and authentic portrait are preserved. These career statements come from the firm’s own biography; other company affiliations do not establish personal cash investments, and exact appointment days are not inferred.

Kemal Malik is senior independent director of listed investment company Syncona Limited. Pharmaceutical research and development executive formerly on Bayer’s management board with responsibility for innovation and LEAPS. Joined Syncona Limited’s board in June 2020.

Healthcare technology executive with more than30years of operating and leadership experience. Her current employer Cylinder Health named her CEO onMarch19,2026 and confirms that she previously led BeMe through its sale, after serving as Clarify Health CEO. Earlier leadership included Diameter Health, IBM Watson Health, Wellcentive, Misys and UnitedHealthcare. BeMe CEO affiliation is historical.

Melanie Gee is chair of listed investment company Syncona Limited. Investment banking adviser and listed-company director. Joined Syncona Limited’s board in June 2019; earlier worked at Lazard, SG Warburg and UBS.

William Dutson is a group accountant at Syncona Investment Management Limited. Chartered accountant trained in PwC’s asset and wealth management assurance practice. Holds a Surrey economics degree.

Clinical psychologist and Yale psychiatry faculty member focused on access, evidence-based mental-health care and digital intervention. Her current Yale biography explicitly describes her BeMe chief clinical officer service as2023–2024. She is not recorded as a current independent BeMe executive.

Stephen Molumby is a head of portfolio management and fp&a at Syncona Investment Management Limited. CIMA-qualified finance professional previously working in financial planning and commercial finance at Wellcome and Sky. Studied business at Trinity College Dublin and Manchester.

Clinical psychologist and behavioral-health researcher, named BeMe chief clinical officer in its2021launch. Her investor biography describes youth substance-use and social-media intervention research and prior clinical leadership at Hopelab. Later BeMe sources name Amber Childs in the clinical leadership position, so Ramo’s role is historical.

Sarah Qian is a associate at Syncona Investment Management Limited. Endocrinologist and investor previously at ARCHIMED. Trained clinically in Melbourne and London, holds a Monash medical degree and London Business School MBA.

Sarah Crabtree is a head of legal (transactions) at Syncona Investment Management Limited. Transaction lawyer previously corporate and commercial counsel at Vue International. Earlier advised private equity clients on acquisitions and exits; studied law at Nottingham.

Child, adolescent and adult psychiatrist and digital-health medical executive. Her own website identifies her current Headway chief medical officer role. She was BeMe chief medical officer at launch and personally announced her departure inApril2023; this BeMe affiliation is historical.

Samantha Roberts is a managing director at Syncona Investment Management Limited. Clinician and healthcare leader formerly chief executive of NICE. Leads day-to-day operations at SIML as managing director under the September 2026 leadership changes and serves on Spur’s board.

Roel Bulthuis is a executive partner at Syncona Investment Management Limited. Life sciences investor with venture capital, business development and banking experience. Formerly Syncona’s managing partner and head of investments; became an executive partner under the September 2026 leadership changes.

Richard Wooster is a executive partner at Syncona Investment Management Limited. Drug discovery executive whose earlier scientific leadership roles included Translate Bio and Tarveda Therapeutics. Also serves as scientific leader and director of Slingshot Therapeutics.

Raghd Rostom is a principal at Syncona Investment Management Limited. Biopharmaceutical investor with a background in Boston Consulting Group’s healthcare practice. Has helped establish Kesmalea and Yellowstone and serves on portfolio company boards.

Pierre Joffrin is a senior associate at Syncona Investment Management Limited. Biotechnology company builder and investor previously at Jeito and OSE. Was Mogrify’s first employee and corporate development officer; studied biochemistry and pharmacology.

Nisha Sethi is a legal counsel at Syncona Investment Management Limited. Legal professional previously advising corporate service provider Animo Associates. Qualified at Noble Solicitors and studied law at Reading.

Nikki Padden is a corporate partner at Syncona Investment Management Limited. Chartered accountant with earlier operations and project roles at GlaxoSmithKline and AEA Technology. Holds a biotechnology doctorate from King’s College London and a Warwick MBA.

Nathaniel Dahan is a principal at Syncona Investment Management Limited. Biopharmaceutical investor with earlier life sciences M&A consulting experience at Deloitte. Holds a UCL biomedical engineering doctorate and conducted postdoctoral research at Imperial College.

Melina Hoffmann is a associate at Syncona Investment Management Limited. Biotechnology researcher and investor previously at BioGeneration Ventures and Valink Therapeutics. Her research experience includes Pheon Therapeutics and the Institute of Cancer Research.

Marc Perkins is a general counsel at Syncona Investment Management Limited. Corporate lawyer previously serving as general counsel and company secretary at Abcam. Earlier worked at Herbert Smith Freehills on public and private M&A.

Kenneth Galbraith is a chair of siml and executive partner at Syncona Investment Management Limited. Biotechnology executive and investor with experience as CEO, CFO, director and venture capital manager in North America. The current Syncona roster identifies him as SIML chair and executive partner.

Kate Butler is a chief financial officer at Syncona Investment Management Limited. Finance executive who joined Syncona in 2022 and became CFO in April 2024. Earlier roles included CFO of Awakn and finance leadership at Kite Europe, Gilead and Vectura.

Hitesh Thakrar is a executive partner at Syncona Investment Management Limited. Public equities and venture investor with experience managing innovation strategies at Aviva and ADIA. His interests include data science and medical diagnostics, and he has served as an Alan Turing Institute trustee. Hitesh Thakrar is publicly named by Cambridge Angels in its selected individual-member directory. Membership is an angel-network affiliation: individual investment choices are independent, and membership alone does not prove personal investment in any portfolio company.

Helen D'Silva is a executive assistant at Syncona Investment Management Limited. Executive support professional previously working at Gardiner and Theobald, the Big Lottery Fund and Land Securities.

Harriet Gower Isaac is a chief people officer at Syncona Investment Management Limited. Human resources executive with international pharmaceutical experience. Previously led European HR at Alcon and held senior HR positions at GSK and Novartis.

Rishi Kayathi publicly announced a summer2026 affiliation with Watershed Ventures, meeting and investing in founders; his precise title is not independently disclosed. Columbia’s2025–2026 venture fellows biography identifies a UCLA neuroscience degree, prior life-sciences consulting at DeciBio and advisory work at Clear Labs, with interests in physical AI, robotics and frontier technology. Earlier mental-health app work is biographical experience, not an inferred Watershed personal investment.

Zain Khanna, also using Zen, interned with Watershed Ventures in2025 through Columbia’s social enterprise summer fellowship. His university account describes sourcing and screening opportunities, market research, startup due diligence and investment committee work. He is a Columbia MBA class of2026 fellow with a background in chemistry and economics. His internship and later public representation are qualified; a permanent appointment is not inferred.

Mubarak Alliyu announced joining Watershed Ventures as a summer associate in2024, an appointment welcomed by partner Momo Bi. He studied at Stanford Graduate School of Business in the class of2025. His published interview describes earlier chemical-engineering studies at the University of Lagos and Imperial College London and finance, energy and risk experience. The summer appointment is qualified historically rather than asserted as current permanent employment.

Zunaira Arshad publicly represented Watershed Ventures in investment announcements and an investor networking event in2024–2025. Her own account describes work on the firm’s investments in Tabs and Penguin AI. Her current professional headline refers to building something new; no later Watershed employment or promotion is inferred. An authentic individual portrait could not be retrieved; unrelated namesakes in Pakistan were excluded.

Momo Bi is published as a partner of Watershed Ventures by Cornell Tech’s2025 event account and her public event profile. She has participated in venture-capital and entrepreneurship programming and welcomed a Watershed summer associate in2024. Her current professional profile lists Stealth, so the later status of her operating partner affiliation is not independently established. Her public education record identifies Cornell’s graduate business program.

Danish Munir co-founded Watershed Ventures and was identified as an investment committee member and venture partner in primary2023 conference and event material. The current Watershed filing does not independently establish a continuing committee appointment. He is also a founding partner of GreyMatter, whose own current directory publishes his portrait. Earlier, he co-founded Genoa Telepsychiatry, formerly 1DocWay, before its acquisition by Optum, and worked at Microsoft. Founding Partner of GreyMatter Capital focused on mental and brain health. He founded Genoa Telepsychiatry, formerly1DocWay, before its acquisition by Optum, where he worked on behavioral-health network innovation. He began his career at Microsoft and studied computer information sciences at the University of Pennsylvania. GreyMatter’s published biography notes his angel-investment activity; no particular personal cash check is inferred from institutional portfolio membership.

Samir Malik is a Watershed venture partner in the firm’s published event account and remains a named manager of several Watershed vehicles in its March2026 SEC filing. His published healthcare biography describes founding 1DocWay, leading Genoa Telepsychiatry and later serving as CEO of firsthand, which supports people with serious mental illness. He previously worked in healthcare operations and consulting. These outside-company positions are biographical context, not additional imported current roles or personal investments. Samir Malik is publicly listed as an advisor to GreyMatter Capital. The manager’s own directory describes the professional background as: Co-founder & EVP, Genoa Telepsychiatry, Optum Behavioral Health. This directory caption describes outside affiliations and experience; it does not establish current employment at those organizations or a GreyMatter executive position.

Imraan Ahmed leads Watershed Ventures and is the manager of its legal adviser Watershed Collective LLC, according to its March2026 SEC filing. His Kauffman Fellows biography describes earlier health-technology investing at Armory Square Ventures and Radius Ventures, as well as home-health entrepreneurship, private equity and investment banking experience. He studied finance at the University of Maryland and earned an MBA at Columbia Business School.

Gwenaelle Pemberton is a executive partner at Syncona Investment Management Limited. Regulatory affairs specialist whose career includes Gilead, Pfizer, Pharmacia and AstraZeneca. Advises Syncona on regulatory strategy and investment decisions.

Gonzalo Garcia is a partner at Syncona Investment Management Limited. Biopharmaceutical investor and company builder with earlier experience as a Boston Consulting Group project leader. Holds a Cambridge doctorate in protein biophysics.

Gemma Mountford is a executive assistant at Syncona Investment Management Limited. Executive support professional with earlier investment banking experience, including supporting European M&A and business services leaders at Canaccord Genuity.

Fiona Fernandez is a head of operations at Syncona Investment Management Limited. Operations professional at Syncona since 2013, overseeing technology and facilities. Previously provided executive support at AnaCap Financial Partners and studied geography and management at Leeds.

Elisa Petris is a managing partner at Syncona Investment Management Limited. Founding Syncona team member who helped establish Blue Earth Diagnostics, Quell, Beacon and Achilles. Has held operating and director roles across these life science businesses.

Technology entrepreneur and BeMe co-founder, publicly named chief technology and chief product officer at its2021launch. Previously founded family social-media product Togetherville, acquired by Disney, and worked in Facebook product leadership. Historical BeMe appointment is qualified following its2025Hazel acquisition.

Edward Hodgkin is a managing partner at Syncona Investment Management Limited. Biopharmaceutical executive and investor who helped establish Autolus and Resolution Therapeutics as their initial CEO. Earlier leadership positions included Biotica and BrainCells.

Benjamin (Ben) Vyshedskiy’s own website explicitly lists recruiting for Orbit Engineering from February through July 2026 as a past affiliation and links orbit.engineering. It describes current genetics research at Harvard Medical School, Cambridge natural-sciences studies and Bio-Squared activity beginning August 2026. His scientific publications are personal research credentials, not automatically company publications or an ongoing Orbit employee role. Month-level tenure is retained in the role text without invented exact start or end days.

Wali Qureshi’s own professional profile identifies Orbit Inc. in Boston and studies in data science and biology at Northeastern University. His public research-project description concerns perceptual learning and psychophysics analysis. Orbit’s own company directory independently names his affiliation. No executive title, clinical licence, personal investment or funding-round amount is inferred; this Boston-based researcher is distinct from same-name aerospace professionals elsewhere.

Cindy Woo is a governance and compliance assistant at Syncona Investment Management Limited. Chartered governance professional and secretary. Previously worked at Great Ormond Street Hospital Children’s Charity and in company secretarial positions in Hong Kong.

Ariana Duverge’s own public professional profile lists Orbit Inc. in Boston. She describes work at the intersection of clinical research and emerging technology and publicly recruits clinical research staff for Orbit’s Charlestown research programme. She and Steven Pang announced the Peregrine Prize for clinical-research professionals; that award initiative is distinct from Orbit company financing. The precise current internal job title and appointment day are not public in the accessible primary profile.

Tina Chou, PhD, is a clinical psychologist and psychiatric-neuroscience researcher named in Orbit’s own public affiliation directory. Her own professional profile describes expertise in clinical psychology and neuroscience. Her published author biography identifies a Harvard clinical-psychology doctorate and Brown clinical internship, with research using neuroimaging and brain stimulation. Orbit does not publish a precise current title on its public directory, so this record does not infer employment status, an executive appointment or a medical degree.

Spencer Green’s own public professional profile lists Orbit Inc. in Boston and Massachusetts Institute of Technology studies on leave. A first-hand April 2025 Orbit interview names him among the team members who joined the company after it moved to Boston. The Eigenprize’s own programme page also names Green as an organizer. No specific executive title, equity ownership or programme co-funder identity is inferred from these affiliations.

Clinical psychologist known as Nicki Tessler, co-founder of BeMe Health. Her primary investor biography describes more than20years of behavioral-health leadership and prior executive work at Universal Health Services. She stepped down as BeMe CEO inJune2025; founder status does not imply current operating management.

Christina Seed is a group reporting and treasury manager at Syncona Investment Management Limited. Chartered accountant overseeing financial reporting and treasury. Trained at Deloitte in investment funds and joined Syncona in 2020; holds a Warwick biomedical sciences degree.

Chris Hollowood is a chief executive officer and chief investment officer at Syncona Investment Management Limited. Life science investor at Syncona since its 2012 launch. His work includes building gene therapy companies addressing eye, liver, kidney and central nervous system diseases.

Mark Khrapko’s own website identifies his work as neurotechnology at Orbit, links the exact orbit.engineering domain and publishes his company email. A first-hand April 2025 interview names him as a member of the Orbit team. His own site shows hands-on electrode, EEG and prototype engineering work. He is also named as an Eigenprize programme organizer; this outward programme role is separate from raising cash for Orbit. No unverified executive title or appointment day is inferred.

Colton El-Habr co-founded Orbit Technologies with Steven Pang in February 2023. Its November 2023 issuer release identifies him as CTO. A first-hand April 2025 interview describes his transfer from Georgetown to Johns Hopkins engineering and departure in 2023 to build Orbit full-time. His public professional profile continues to identify Orbit; the precise current executive title is not independently republished. The Thiel Foundation named him a 2025 fellow alongside Pang.

Steven Pang co-founded Orbit Technologies in February 2023 with Colton El-Habr. The company’s November 2023 issuer release names him co-founder and CEO. He was a Georgetown student when developing the non-invasive vestibular-neurostimulation venture, and the Thiel Foundation named him a 2025 fellow. His public professional profile and the current company directory retain the Orbit affiliation. Founder fellowship support is distinct from company equity financing.

Caroline Horsford is a executive assistant at Syncona Investment Management Limited. Provides executive support to the board and investor relations team. Previously supported marketing and research leadership at Odgers Berndtson; studied Hispanic studies and history at Nottingham.

Annabel Clark is a head of corporate affairs at Syncona Investment Management Limited. Corporate communications specialist previously advising investment and corporate clients at Greenbrook Communications. Studied history at Bristol.

Anastasia Prechistenskaya is a people partner at Syncona Investment Management Limited. Human resources professional whose earlier roles included Alcon, Diageo, Groupe SEB and Sanofi, with regional responsibilities in Russia, Europe and the UK.

Alessio D'addabbo is a analyst at Syncona Investment Management Limited. Biological scientist with a Southampton PhD studying HIV vaccine design using biophysics and glycobiology. Previously interned at Syncona and Resolution Therapeutics.

Head of Healthworx Accelerator, as identified in the platform’s August 2025 interview. Her background includes policy work on U.S.–East Asia relations, founding an education technology startup in Beijing, and the Aspen Institute’s Global Leaders Network. She joined the predecessor 1501 Health program in 2022 and supports early healthcare companies with commercial relationships and ecosystem access.

José-Alain Sahel serves as More Team Members with UPMC Enterprises, UPMC’s innovation, commercialization and corporate venture investment division. The organization’s current public team directory and individual biography verify this affiliation. José-Alain is a clinician-scientist studying retinal degeneration and restoration of sight through approaches including gene therapy, optogenetics and artificial retinas. He chairs ophthalmology at the University of Pittsburgh and founded the UPMC Vision Institute in 2023. His Enterprises role connects ophthalmic research and clinical expertise to commercialization.

David Okonkwo serves as More Team Members with UPMC Enterprises, UPMC’s innovation, commercialization and corporate venture investment division. The organization’s current public team directory and individual biography verify this affiliation. David is a University of Pittsburgh neurological-surgery professor who joined Enterprises in 2018 to focus on medical technology and neuroscience. He helps develop partnerships through UPMC’s Health Technology Advancement Program. He earned an MD and PhD at Virginia Commonwealth University and trained in neurosurgery at the University of Virginia.

Chris Waters serves as More Team Members with UPMC Enterprises, UPMC’s innovation, commercialization and corporate venture investment division. The organization’s current public team directory and individual biography verify this affiliation.

Kritika Verma serves as More Team Members with UPMC Enterprises, UPMC’s innovation, commercialization and corporate venture investment division. The organization’s current public team directory and individual biography verify this affiliation.

Fabian Tenenbaum serves as More Team Members with UPMC Enterprises, UPMC’s innovation, commercialization and corporate venture investment division. The organization’s current public team directory and individual biography verify this affiliation. Fabian leads the division’s venture strategy, corporate capital deployment and formation of companies across therapeutics, digital health and translational science. His prior executive experience includes Nectin Therapeutics and Bellerophon Therapeutics. His current biography describes responsibility for the corporate evergreen investment platform.

Dan Tarpey serves as More Team Members with UPMC Enterprises, UPMC’s innovation, commercialization and corporate venture investment division. The organization’s current public team directory and individual biography verify this affiliation.

Eliza Swann serves as More Team Members with UPMC Enterprises, UPMC’s innovation, commercialization and corporate venture investment division. The organization’s current public team directory and individual biography verify this affiliation.

Brian Susko serves as More Team Members with UPMC Enterprises, UPMC’s innovation, commercialization and corporate venture investment division. The organization’s current public team directory and individual biography verify this affiliation.

Curtis Stratman serves as More Team Members with UPMC Enterprises, UPMC’s innovation, commercialization and corporate venture investment division. The organization’s current public team directory and individual biography verify this affiliation.

Margaret Steere serves as More Team Members with UPMC Enterprises, UPMC’s innovation, commercialization and corporate venture investment division. The organization’s current public team directory and individual biography verify this affiliation.

Nick Shapiro serves as More Team Members with UPMC Enterprises, UPMC’s innovation, commercialization and corporate venture investment division. The organization’s current public team directory and individual biography verify this affiliation. Nicholas (Nick) Shapiro joined BrainCheck’s board in March2024 representing UPMC Enterprises. UPMC’s own biography confirms the Nick/Nicholas naming identity.

Hank Safferstein serves as More Team Members with UPMC Enterprises, UPMC’s innovation, commercialization and corporate venture investment division. The organization’s current public team directory and individual biography verify this affiliation. Hank combines scientific, legal and business training, including a doctorate in neurobiology. His current Enterprises biography identifies him as Generian Pharmaceuticals CEO and a former founding CEO of Cognition Therapeutics, where he helped advance Alzheimer’s research into clinical development. Earlier roles included biotechnology business development and NIH technology transfer.

Michele Mueser serves as More Team Members with UPMC Enterprises, UPMC’s innovation, commercialization and corporate venture investment division. The organization’s current public team directory and individual biography verify this affiliation.

Anna Mamo serves as More Team Members with UPMC Enterprises, UPMC’s innovation, commercialization and corporate venture investment division. The organization’s current public team directory and individual biography verify this affiliation.

John Lowman serves as More Team Members with UPMC Enterprises, UPMC’s innovation, commercialization and corporate venture investment division. The organization’s current public team directory and individual biography verify this affiliation.

Matthias Kleinz serves as More Team Members with UPMC Enterprises, UPMC’s innovation, commercialization and corporate venture investment division. The organization’s current public team directory and individual biography verify this affiliation.

Soun Khountham serves as More Team Members with UPMC Enterprises, UPMC’s innovation, commercialization and corporate venture investment division. The organization’s current public team directory and individual biography verify this affiliation.

Ashleigh Ketter serves as More Team Members with UPMC Enterprises, UPMC’s innovation, commercialization and corporate venture investment division. The organization’s current public team directory and individual biography verify this affiliation.

Ketki Karanam serves as More Team Members with UPMC Enterprises, UPMC’s innovation, commercialization and corporate venture investment division. The organization’s current public team directory and individual biography verify this affiliation.

Deepan Kamaraj serves as More Team Members with UPMC Enterprises, UPMC’s innovation, commercialization and corporate venture investment division. The organization’s current public team directory and individual biography verify this affiliation.

Matthew Junker serves as More Team Members with UPMC Enterprises, UPMC’s innovation, commercialization and corporate venture investment division. The organization’s current public team directory and individual biography verify this affiliation.

Philip Jones serves as More Team Members with UPMC Enterprises, UPMC’s innovation, commercialization and corporate venture investment division. The organization’s current public team directory and individual biography verify this affiliation. Philip focuses on selecting and translating scientific discoveries into potential medicines. His background includes drug discovery at Merck and establishment of drug-discovery teams at MD Anderson. His current Enterprises role covers science and discovery investment and development, with experience moving research programs into clinical trials.

Jeffrey Jones serves as More Team Members with UPMC Enterprises, UPMC’s innovation, commercialization and corporate venture investment division. The organization’s current public team directory and individual biography verify this affiliation.

Maryam Jalal serves as More Team Members with UPMC Enterprises, UPMC’s innovation, commercialization and corporate venture investment division. The organization’s current public team directory and individual biography verify this affiliation.

Stuart Ingram serves as More Team Members with UPMC Enterprises, UPMC’s innovation, commercialization and corporate venture investment division. The organization’s current public team directory and individual biography verify this affiliation.

Allison Hydzik serves as More Team Members with UPMC Enterprises, UPMC’s innovation, commercialization and corporate venture investment division. The organization’s current public team directory and individual biography verify this affiliation.

Ken Howard serves as More Team Members with UPMC Enterprises, UPMC’s innovation, commercialization and corporate venture investment division. The organization’s current public team directory and individual biography verify this affiliation.

April Hopper serves as More Team Members with UPMC Enterprises, UPMC’s innovation, commercialization and corporate venture investment division. The organization’s current public team directory and individual biography verify this affiliation.

Kelsey Holden serves as More Team Members with UPMC Enterprises, UPMC’s innovation, commercialization and corporate venture investment division. The organization’s current public team directory and individual biography verify this affiliation.

Angélica Herrera serves as More Team Members with UPMC Enterprises, UPMC’s innovation, commercialization and corporate venture investment division. The organization’s current public team directory and individual biography verify this affiliation.

Kathryn Heffernan serves as More Team Members with UPMC Enterprises, UPMC’s innovation, commercialization and corporate venture investment division. The organization’s current public team directory and individual biography verify this affiliation.

Julian Hassinger serves as More Team Members with UPMC Enterprises, UPMC’s innovation, commercialization and corporate venture investment division. The organization’s current public team directory and individual biography verify this affiliation.

Valerie Harrison serves as More Team Members with UPMC Enterprises, UPMC’s innovation, commercialization and corporate venture investment division. The organization’s current public team directory and individual biography verify this affiliation.

Kathy Griffin serves as More Team Members with UPMC Enterprises, UPMC’s innovation, commercialization and corporate venture investment division. The organization’s current public team directory and individual biography verify this affiliation.

Matthew Grant serves as More Team Members with UPMC Enterprises, UPMC’s innovation, commercialization and corporate venture investment division. The organization’s current public team directory and individual biography verify this affiliation.

David Gibson serves as More Team Members with UPMC Enterprises, UPMC’s innovation, commercialization and corporate venture investment division. The organization’s current public team directory and individual biography verify this affiliation.

Sara Fest serves as More Team Members with UPMC Enterprises, UPMC’s innovation, commercialization and corporate venture investment division. The organization’s current public team directory and individual biography verify this affiliation.

Randall Dye serves as More Team Members with UPMC Enterprises, UPMC’s innovation, commercialization and corporate venture investment division. The organization’s current public team directory and individual biography verify this affiliation.

Don DeCorte serves as More Team Members with UPMC Enterprises, UPMC’s innovation, commercialization and corporate venture investment division. The organization’s current public team directory and individual biography verify this affiliation.

Jeanne Cunicelli serves as More Team Members with UPMC Enterprises, UPMC’s innovation, commercialization and corporate venture investment division. The organization’s current public team directory and individual biography verify this affiliation. A life-sciences venture investor formerly at Bay City Capital, Jeanne joined UPMC in 2017 and became Enterprises president in January 2021. She oversees the division’s translational-science and digital-health investment and company-building activities. Her education includes cognitive psychology at Carnegie Mellon and an MBA from the University of San Francisco.

Tyler Crawford serves as More Team Members with UPMC Enterprises, UPMC’s innovation, commercialization and corporate venture investment division. The organization’s current public team directory and individual biography verify this affiliation.

Carly Cook serves as More Team Members with UPMC Enterprises, UPMC’s innovation, commercialization and corporate venture investment division. The organization’s current public team directory and individual biography verify this affiliation.

Parker Cahn serves as More Team Members with UPMC Enterprises, UPMC’s innovation, commercialization and corporate venture investment division. The organization’s current public team directory and individual biography verify this affiliation.

Brent Burns serves as More Team Members with UPMC Enterprises, UPMC’s innovation, commercialization and corporate venture investment division. The organization’s current public team directory and individual biography verify this affiliation.

Julia Bennett serves as More Team Members with UPMC Enterprises, UPMC’s innovation, commercialization and corporate venture investment division. The organization’s current public team directory and individual biography verify this affiliation.

James Bauersmith serves as More Team Members with UPMC Enterprises, UPMC’s innovation, commercialization and corporate venture investment division. The organization’s current public team directory and individual biography verify this affiliation.

Craig Ball serves as More Team Members with UPMC Enterprises, UPMC’s innovation, commercialization and corporate venture investment division. The organization’s current public team directory and individual biography verify this affiliation.

Rosheema Bala serves as More Team Members with UPMC Enterprises, UPMC’s innovation, commercialization and corporate venture investment division. The organization’s current public team directory and individual biography verify this affiliation.

Nicole Ansani serves as More Team Members with UPMC Enterprises, UPMC’s innovation, commercialization and corporate venture investment division. The organization’s current public team directory and individual biography verify this affiliation.

Alexander J. Anetakis serves as More Team Members with UPMC Enterprises, UPMC’s innovation, commercialization and corporate venture investment division. The organization’s current public team directory and individual biography verify this affiliation.

Andrew Adrian-Karlin serves as More Team Members with UPMC Enterprises, UPMC’s innovation, commercialization and corporate venture investment division. The organization’s current public team directory and individual biography verify this affiliation.

Alan Ashworth is a scientific adviser at Overwater Ventures. His cancer-research career includes discovering BRCA2 and work on synthetic lethality underlying PARP-inhibitor treatment approaches. Overwater’s biography describes UCSF cancer-center leadership and scientific co-founding of Tango Therapeutics; these outside affiliations remain source-qualified.

Carolyn Coles-Devine leads platform and operations at Overwater Ventures, supporting firm infrastructure and portfolio-company commercialization. Her prior operating career includes leadership at lululemon, Canada Goose and Northern Reflections. She focuses on teams, founder relationships and practical growth support.

Ivy Ross is a venture partner at Overwater Ventures. Her design career includes Google consumer-device hardware and senior roles across major consumer brands. She co-authored Your Brain on Art, exploring connections between creativity and neuroscience. Outside-employer titles reproduced in Overwater’s biography are historical context unless separately confirmed current.

Maria Molland is an adviser at Overwater Ventures and an investor, operator and board director. She previously led Thinx as CEO through its acquisition by Kimberly-Clark in 2022. Her career includes executive roles at eBay, Yahoo, Thomson Reuters, Dow Jones, Fab.com and Disney.

Kristina Simmons is the founder and managing partner of Overwater Ventures. She previously worked in market development at Andreessen Horowitz and as a chief of staff and investment partner at Khosla Ventures. Earlier, she helped build lululemon’s digital channels and emerging-products initiatives. She leads Overwater’s early-stage investment and founder-support strategy.

Amanda Duckworth is a communications advisor to Define Ventures. Her work covers reputation management, marketing and crisis communications. Earlier leadership roles included Kleiner Perkins and Brunswick Group, alongside communications work for investment banks and a law firm. Her published biography describes legal education in the United Kingdom.

Debby Meredith is a technology advisor to Define Ventures. She has worked with engineering and product teams, including founder support and venture operating roles at Mohr Davidow Ventures. Earlier positions included Netscape, Collabra Software, Slate Corporation and other technology businesses. She studied computer science at Stanford and computer science and mathematics at the University of Michigan.

Bangaly Kaba is a consumer advisor to Define Ventures. Its biography describes product-management leadership at YouTube, earlier work at Reforge, Instacart, Instagram and Facebook, and experience advising consumer-technology companies. His advisory role does not imply a personal investment in any portfolio company.

Ashley Yuki Alexander, also named Ashley Alexander in her biography, is listed by Define Ventures as a former consumer advisor. Its updated biography identifies her as vice president of product for healthcare at OpenAI and describes earlier product leadership at Instagram. She studied engineering, computer science and business at the University of Pennsylvania and Wharton. Her Define affiliation is explicitly historical, with appointment and departure dates unpublished.

Peter Fine is a healthcare advisor to Define Ventures. He led Banner Health from 2000 until June2024, following leadership roles at Aurora Health Care and other hospital organizations. His biography describes healthcare-administration education at George Washington University and undergraduate study at Ohio University. The historical CEO role is not presented as a current executive appointment.

Earlier source-recorded professional biography (outside roles may have changed; source provenance retained): Seth Cohen is a commercial advisor to Define Ventures. Its biography identifies him as president and a director of Cedar and previously CEO and co-founder of OODA Health, which Cedar acquired in 2021. His earlier experience includes Castlight Health and McKinsey, with graduate study at Harvard and undergraduate study at Stanford. Insight Partners source, reviewed October 8, 2026: As P&G’s Chief Information Officer, Seth Cohen is responsible for elevating the company’s digital transformation strategy to improve the consumer experience and deliver business growth. Cohen brings unique perspective on how to leverage cutting-edge technologies to transform the retail space and advance internal processes. He has a proven track record for building world-class IT functions and developing top talent to become future industry leaders. Cohen has spent over 30 years working in consumer goods and retail industries. Most recently, he led PepsiCo’s IT function in delivering capabilities across all aspects of the value chain. Prior to his tenure at PepsiCo, Cohen was global CIO for Reckitt Benckiser Group, (RB) responsible for leading the company’s IT transformation including major systems deployments, upgrades and integrations. Cohen and his wife of 21 years have four children and reside in Dallas Texas, with plans to relocate to Cincinnati, OH in 2025.

A.G. Breitenstein is a healthcare advisor to Define Ventures. Its biography identifies her as founder and executive chair of FOLX Health, a healthcare platform serving LGBTQIA+ communities. She previously co-founded Optum Ventures and Humedica and held product leadership roles at Optum Analytics. Her education includes public health, law and undergraduate study at Harvard, the University of Connecticut and Yale.

Jim Pursley is a commercial advisor to Define Ventures. Its biography identifies him as president of Hinge Health and describes earlier commercial leadership at Livongo, Care Innovations and GE Healthcare. He studied management science and information systems at Penn State and earned an MBA at Northwestern’s Kellogg School.

Beth Bierbower, also named Elizabeth Bierbower in her biography, is a healthcare advisor to Define Ventures. Her experience spans health-insurance leadership, managed care and digital-health partnerships, including senior leadership at Humana. Her published biography also describes board work with healthcare services and technology companies.

Jia Li is an AI advisor to Define Ventures. Its published biography identifies her as co-founder, president and chief AI officer of LiveX AI and describes earlier AI research leadership at Google Cloud and Snap. She earned a computer-science PhD at Stanford and has worked on AI applications in medicine and public-interest settings.

Katharine Morris is administrative assistant and office manager at Define Ventures. She previously worked in development at the San Francisco Zoological Society and guest services at the Commonwealth Club. She studied philosophy and religious studies at the University of San Francisco.

Erin Hardy is accounting and operations manager at Define Ventures. Her prior experience includes client relationship management at Mariner Wealth Advisors and fund accounting and administration at Aduro Advisors. Her published education includes accounting and finance at Chapman University.

Lauren O’Mahony leads marketing at Define Ventures. Her earlier experience includes senior marketing and communications leadership at Carta, fractional communications leadership at Digit, public relations at Mighty Public Relations and Eventbrite. She supports how the venture firm and its founders communicate their work.

Shannon Knous is vice president of finance and operations at Define Ventures. Her earlier experience includes fund administration and controller work at Aduro Advisors and public accounting at BDO USA. Her published biography identifies her as a Colorado licensed certified public accountant and a UCLA economics graduate.

Karsten Vagner leads people operations at Define Ventures. He previously held people leadership roles at Maven Clinic, Hired, AppNexus and Zocdoc, supporting recruiting, organizational growth and company leadership.

Garrett Howard is a principal at Define Ventures. His background includes healthcare company building and buyouts at Rubicon Founders, venture and growth investing at Longitude Capital, healthcare investment banking at Lazard and finance work at Pantheryx. He studied at Wharton and the University of Colorado.

Chuka Esiobu is a principal at Define Ventures. His earlier roles included healthcare venture investing at Bessemer Venture Partners, clinical innovation and strategy at Evolent Health and consulting at Boston Consulting Group. He studied neurobiology at Harvard, conducted thesis research at the Harvard Stem Cell Institute and earned an MBA at Wharton.

Hong Truong is a principal at Define Ventures. Her published experience includes healthcare impact investing at the California Health Care Foundation, health-system venture investing at Cedars-Sinai and MemorialCare, Kaiser Permanente Ventures and health-economics consulting at Analysis Group. She studied public health at Yale and human biology and international relations at Brown.

Michael Wert is a partner at Define Ventures. He previously invested in healthcare technology and services at Longitude Capital and worked in healthcare investing at Warburg Pincus, consulting at McKinsey and investment banking at Merrill Lynch. His education includes Stanford Graduate School of Business and Whitman College.

Chirag Shah is a partner at Define Ventures. His healthcare investing and operating background includes The Carlyle Group, Imagine Health and Castlight Health, with work spanning strategy, analytics and product development. Earlier he worked in investment banking at Morgan Stanley and studied finance and pre-med at New York University.

Carolyn Magill is a venture partner at Define Ventures. Her published experience includes leading Aetion and Remedy Partners, payer strategy and operations at Evolent Health, and operational leadership at UnitedHealth Group. She studied at Wharton and Harvard. Healthcare operating executive and former Aetion CEO. Her primary investor biography describes prior leadership across value-based healthcare organizations. Aetion’s own September2024announcement confirms her transition from CEO to senior adviser. BeMe named her in its combined board/adviser group in2021; no individual director title or current acquired-company appointment is inferred.

Lynne Chou O’Keefe founded Define Ventures and is its managing partner. Her earlier career included healthcare venture investing at Kleiner Perkins, commercial and product leadership at Abbott Vascular and Guidant, enterprise-software investing at Apax Partners and investment banking at Goldman Sachs. Her published education includes Harvard Business School and industrial engineering at Stanford.

Weiren Loh is publicly associated with SUTD’s venture and incubation programs. A direct delivery-partner case study identifies him as SUTD Program Manager in the 2022 Create4Good engagement, and his own public posts describe organizing the university venture ecosystem. His earlier NUS biography identifies him as an NUS Overseas Colleges program manager. A newer Associate Program Director title appears in aggregators but has not been independently verified from a current primary roster and is not imported as confirmed. An authentic matching portrait was not retrievable from the primary NUS page, so no substitute photo is used. A dedicated Venture Innovation Fund investment-decision role or personal investment check is not inferred.

Celestine Khoo Geok Choo is publicly identified by SUTD’s Venture and Incubation Experience office as its Senior Director in a January 2026 award announcement. Her current Far East Hospitality Trust biography describes senior innovation and enterprise leadership at SUTD, following investment-banking experience at DBS and UBS, capital-market and reserve-management roles at the Monetary Authority of Singapore and Asia leadership at Principal Financial Group. These career affiliations are context, not inferred simultaneous employment. Her role is a university venture-office affiliation; no personal Readily cash check or dedicated VIF committee appointment is implied. The matching authentic portrait is a historical photograph published with a named February 2016 appointment report, not represented as a newly taken image.

Peter Longo is Chief Executive Officer of Spectator Health, whose own biography identifies his previous Chief Revenue Officer position at Penguin Ai. Penguin’s September2025 announcement named him as a founding-team member and described earlier healthcare commercial roles at McKesson, Blue Spark Technologies, Sunquest and Sirono. Penguin subsequently appointed Nate Kiely as CRO in May2026; Peter’s exact departure day remains undisclosed.

Marketing director for RAAPID identified as its named press contact in the company’s April 9, 2026 financing release. A genuine named portrait and broader professional biography were not located in the accessible primary sources.

Risk-adjustment consultant listed by RAAPID among its public March 2026 event leadership participants. The company provides an original named portrait. The consultant affiliation is recorded separately from an executive or general employee appointment.

Sales leader named by RAAPID in its March 2026 RISE National leadership listing as a vice president of sales. The issuer publishes his portrait and exact professional name. Further biographical details and appointment dates have not been independently established.

RAAPID commercial leader identified as vice president of sales in the company’s own March 2026 RISE National leadership listing. The issuer publishes an original named portrait; further professional background and tenure dates remain undisclosed.

Commercial leader published by RAAPID as a vice president of sales in its March 2026 RISE National leadership listing. The issuer provides a named original portrait. This record reflects the latest verified issuer-published title and does not infer an employment start date or later promotion.

Co-founder and CMO of RAAPID, as styled in its current official leadership directory. His published background includes more than twenty years in healthcare software and services and co-founding a medical-transcription business whose clinical-data expertise informed RAAPID. The company does not expand the CMO abbreviation in this directory.

Healthcare entrepreneur and founder and chief executive of RAAPID. The company’s own biography describes more than twenty years building healthcare technology and a 2022 launch focused on clinically defensible risk adjustment. He leads the company’s neuro-symbolic AI platform.

The Team8 advisor directory lists Judd Caplain with the external professional title Former Head of Global Financial Services. This is an advisory relationship to Team8, rather than that corporate job title at Team8.

The Team8 advisor directory lists Linda Hill with the external professional title Professor and Leadership Initiative Faculty Chair. This is an advisory relationship to Team8, rather than that corporate job title at Team8.

The Team8 advisor directory lists Rupert Keeley with the external professional title Former PayPal Europe CEO. This is an advisory relationship to Team8, rather than that corporate job title at Team8.

The Team8 advisor directory lists Omri Dahan with the external professional title Former CRO. This is an advisory relationship to Team8, rather than that corporate job title at Team8.

The Team8 advisor directory lists Harit Talwar with the external professional title Board Member. This is an advisory relationship to Team8, rather than that corporate job title at Team8.

The Team8 advisor directory lists Liran Amrany with the external professional title President. This is an advisory relationship to Team8, rather than that corporate job title at Team8.

The Team8 advisor directory lists Vicky Bindra with the external professional title CEO. This is an advisory relationship to Team8, rather than that corporate job title at Team8.

The Team8 advisor directory lists Tomer Barel with the external professional title President. This is an advisory relationship to Team8, rather than that corporate job title at Team8.

The Team8 advisor directory lists Dr. Shlomit Wagman with the external professional title Chief Compliance Officer. This is an advisory relationship to Team8, rather than that corporate job title at Team8.

The Team8 advisor directory lists Mariano Belinky with the external professional title Former Private Investor. This is an advisory relationship to Team8, rather than that corporate job title at Team8.

The Team8 advisor directory lists Ido Gileadi with the external professional title Executive Advisor. This is an advisory relationship to Team8, rather than that corporate job title at Team8.

The Team8 advisor directory lists Dr. Sachin Jain with the external professional title President and CEO. This is an advisory relationship to Team8, rather than that corporate job title at Team8.

The Team8 advisor directory lists Laizer Kornwasser with the external professional title Strategic Healthcare Advisor. This is an advisory relationship to Team8, rather than that corporate job title at Team8.

The Team8 advisor directory lists Christopher Ott MD, FACEP with the external professional title Former CMO Physician Services. This is an advisory relationship to Team8, rather than that corporate job title at Team8.

Previously, he founded Payoneer, serving as its CEO and President. Before this, he co-founded Borderfree (NASDAQ: BRDR), a service provider that expedites cross-border ecommerce and payments for many large online and offline retailers, and was its CEO from 1999–2005. Yuval also served as VP of Business Development for Radware (NASDAQ: RDWR).

He is an experienced investor who provides strategic business leadership and guidance to the fund and its portfolio companies, and serves as a board member to a large number of businesses.

Yael brings 5 years of experience as an office manager at a boutique law firm, where she developed excellent operational skills and a deep understanding of office and personal management.

She currently lives in Hod Hasharon, is married to Benji, and is the proud mother of a 3-year-old son, Lavi. Her hobbies include attending children’s performances and visiting play centers.

Team8’s Talent Acquisition Manager. Her mission is to find the best talents to create and build Team8’s new cybersecurity, data science, fintech and Digital health companies.Formerly Talent Acquisition Specialist at Peacn.ai.

Lorem ipsum dolor sit amet, consectetuer adipiscing elit, sed diam nonummy nibh euismod tincidunt ut laoreet dolore magna aliquam erat volutpat. Ut wisi enim ad minim veniam, quis nostrud exerci tation ullamcorper suscipit lobortis nisl ut aliquip ex ea commodo consequat. Duis autem vel eum iriure dolor in hendrerit in vulputate velit esse molestie consequat, vel illum dolore eu feugiat nulla facilisis at vero eros et accumsan et iusto odio dignissim qui blandit praesent luptatum zzril delenit augue duis dolore te feugait nulla facilisi

Prior to joining Team8, Varda co-founded and served as the Chief Medical Officer of Alike. Health. As Founder and CEO of Maccabi’s Institute for Research and Innovation KSM, she established the first medical informatics program in Israel and pioneered its computerized medical and registry systems.

Uri is a veteran technology leader and startup founder with over two decades of experience in building and architecting innovative systems. His last startup, Spectral, was acquired by Check Point. Uri was the Co-Founder & Chief Architect at Spectral, a startup that empowers teams to develop and deploy secure software at scale. After the acquisition, Uri became the Principal Architect of Cloud Security at Check Point, where he led the research and technology strategy for the cloud division.

Tomer is a technology leader with deep experience in research and software development. Before joining us, he spent five years at Paragon, where he served as Director of the iOS Division. In that role, he led a team of 30 developers and researchers, building advanced low-level intelligence tools and capabilities in collaboration with governmental agencies.

Previously, he served as Chief Information Security Officer at SolarWinds, having joined the company in 2017 as Vice President of Security before stepping into the CISO role where he oversaw

Before joining Team8, she held roles at DocuSign, Bringg, JFrog, and most recently led marketing at Sightfull. She is passionate about using AI, analytics and automation to streamline operations and accelerate pipeline generation.

Before joining Team8, Tamar worked as a Business Development Coordinator in the Agtech sector at the Israel Export Institute. Tamar holds a B.A. in Government and Sustainability from Reichman University, and while completing her studies, she spent two years working at the Foreign Ministry’s Asia and Pacific Division.

Before joining Team8, Tal served as a Brand Manager for Vulcan Cyber, a Tel Aviv-based cybersecurity startup, where she played a key role in shaping the company’s brand and positioning its platform as a leader in exposure and vulnerability management for enterprises.